CA2549463A1 - Cytotoxins and diagnostic imaging agents comprising hsp90 ligands - Google Patents
Cytotoxins and diagnostic imaging agents comprising hsp90 ligands Download PDFInfo
- Publication number
- CA2549463A1 CA2549463A1 CA002549463A CA2549463A CA2549463A1 CA 2549463 A1 CA2549463 A1 CA 2549463A1 CA 002549463 A CA002549463 A CA 002549463A CA 2549463 A CA2549463 A CA 2549463A CA 2549463 A1 CA2549463 A1 CA 2549463A1
- Authority
- CA
- Canada
- Prior art keywords
- hsp90
- composition
- cells
- compound
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 28
- 239000012216 imaging agent Substances 0.000 title claims abstract description 7
- 231100000599 cytotoxic agent Toxicity 0.000 title claims description 8
- 238000002059 diagnostic imaging Methods 0.000 title abstract description 3
- 239000002619 cytotoxin Substances 0.000 title description 3
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 title 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 title 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 76
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 6
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 6
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 79
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims description 33
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- -1 124h 125I Chemical compound 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 19
- 229940127089 cytotoxic agent Drugs 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 6
- 108010006654 Bleomycin Proteins 0.000 claims description 6
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 6
- 229940034982 antineoplastic agent Drugs 0.000 claims description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 6
- 239000002254 cytotoxic agent Substances 0.000 claims description 6
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 6
- 229960001924 melphalan Drugs 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 6
- 238000002600 positron emission tomography Methods 0.000 claims description 6
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 4
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229960004961 mechlorethamine Drugs 0.000 claims description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003600 podophyllotoxin derivative Substances 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 claims description 3
- MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 claims description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 3
- SXFWKZNLYYRHMK-UHFFFAOYSA-N 1h-indolo[7,6-f]quinoline Chemical class C1=CC=C2C3=C(NC=C4)C4=CC=C3C=CC2=N1 SXFWKZNLYYRHMK-UHFFFAOYSA-N 0.000 claims description 3
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 3
- GQGVBSHMRYHBTF-UOWFLXDJSA-N 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 GQGVBSHMRYHBTF-UOWFLXDJSA-N 0.000 claims description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 108010000817 Leuprolide Proteins 0.000 claims description 3
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 claims description 3
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 claims description 3
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 claims description 3
- 229930192392 Mitomycin Natural products 0.000 claims description 3
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 claims description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 3
- 241000863480 Vinca Species 0.000 claims description 3
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229960000473 altretamine Drugs 0.000 claims description 3
- 229960003896 aminopterin Drugs 0.000 claims description 3
- 150000001556 benzimidazoles Chemical class 0.000 claims description 3
- 229960000997 bicalutamide Drugs 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 claims description 3
- 229930188550 carminomycin Natural products 0.000 claims description 3
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 claims description 3
- 229950001725 carubicin Drugs 0.000 claims description 3
- 150000001789 chalcones Chemical class 0.000 claims description 3
- 235000005513 chalcones Nutrition 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960003901 dacarbazine Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 3
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 3
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 3
- 229960001842 estramustine Drugs 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960000752 etoposide phosphate Drugs 0.000 claims description 3
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 3
- 229960002074 flutamide Drugs 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000003966 growth inhibitor Substances 0.000 claims description 3
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000367 immunologic factor Substances 0.000 claims description 3
- 150000002475 indoles Chemical class 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 3
- 229960004338 leuprorelin Drugs 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 claims description 3
- 239000002777 nucleoside Substances 0.000 claims description 3
- 125000003835 nucleoside group Chemical group 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 3
- 229950004406 porfiromycin Drugs 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims description 3
- 150000003212 purines Chemical class 0.000 claims description 3
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 claims description 3
- 229930192524 radicicol Natural products 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- 229960001196 thiotepa Drugs 0.000 claims description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001099 trimetrexate Drugs 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 3
- 229960004355 vindesine Drugs 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 230000003388 anti-hormonal effect Effects 0.000 claims description 2
- 238000009104 chemotherapy regimen Methods 0.000 claims description 2
- 229940080856 gleevec Drugs 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 229960001237 podophyllotoxin Drugs 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 claims 1
- 229940006110 gallium-67 Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229940055742 indium-111 Drugs 0.000 claims 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 claims 1
- 229940044173 iodine-125 Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 52
- 230000027455 binding Effects 0.000 description 26
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 24
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 22
- 238000003556 assay Methods 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 229960002685 biotin Drugs 0.000 description 12
- 235000020958 biotin Nutrition 0.000 description 12
- 239000011616 biotin Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 108090001008 Avidin Proteins 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229960000885 rifabutin Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 108010090804 Streptavidin Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010006519 Molecular Chaperones Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101150029707 ERBB2 gene Proteins 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000005431 Molecular Chaperones Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000009137 competitive binding Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- VWLWTJHKQHRTNC-UHFFFAOYSA-L dipotassium;8-anilino-5-(4-anilino-5-sulfonatonaphthalen-1-yl)naphthalene-1-sulfonate Chemical compound [K+].[K+].C=12C(S(=O)(=O)[O-])=CC=CC2=C(C=2C3=CC=CC(=C3C(NC=3C=CC=CC=3)=CC=2)S([O-])(=O)=O)C=CC=1NC1=CC=CC=C1 VWLWTJHKQHRTNC-UHFFFAOYSA-L 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 239000008196 pharmacological composition Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241001432959 Chernes Species 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 2
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- LYQFWZFBNBDLEO-UHFFFAOYSA-M caesium bromide Chemical compound [Br-].[Cs+] LYQFWZFBNBDLEO-UHFFFAOYSA-M 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PKQIDSVLSKFZQC-UHFFFAOYSA-N 3-oxobutanal Chemical compound CC(=O)CC=O PKQIDSVLSKFZQC-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- CCSGGWGTGOLEHK-OBJOEFQTSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(5-aminopentyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCN)SC[C@@H]21 CCSGGWGTGOLEHK-OBJOEFQTSA-N 0.000 description 1
- KIJSBKNJFAUJFV-ZOBUZTSGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCOCCOCCOCCN)SC[C@@H]21 KIJSBKNJFAUJFV-ZOBUZTSGSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101100515516 Arabidopsis thaliana XI-H gene Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 102100020977 DnaJ homolog subfamily A member 1 Human genes 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 101000931227 Homo sapiens DnaJ homolog subfamily A member 1 Proteins 0.000 description 1
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- BQWLWNOFIHHESO-UHFFFAOYSA-N Kinamycin C Natural products C1=CC=C2C(=O)C(C3=C(N4C#N)C(OC(C)=O)C(C)(O)C(OC(C)=O)C3OC(=O)C)=C4C(=O)C2=C1O BQWLWNOFIHHESO-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZVCNREZZUJIBAG-UHFFFAOYSA-N Prekinamycin Chemical compound C1=CC=C2C(=O)C(C3=C(O)C=C(C=C3[C-]3[N+]#N)C)=C3C(=O)C2=C1O ZVCNREZZUJIBAG-UHFFFAOYSA-N 0.000 description 1
- ICZJRSZSGQYRIC-UHFFFAOYSA-N Prekinamycin Natural products C1=CC=C2C(=O)C(C3=C(O)C=C(C=C3N3C#N)C)=C3C(=O)C2=C1O ICZJRSZSGQYRIC-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 108700038496 S-(4-azidophenacyl)glutathione Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000304160 Sarcophaga carnaria Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108700011582 TER 286 Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241001523432 Zale Species 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LBGCRGLFTKVXDZ-UHFFFAOYSA-M ac1mc2aw Chemical compound [Al+3].[Cl-].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 LBGCRGLFTKVXDZ-UHFFFAOYSA-M 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- LWISPDYGRSGXME-YDHLFZDLSA-N biotin peg2 amine Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCOCCOCCN)SC[C@@H]21 LWISPDYGRSGXME-YDHLFZDLSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- OJLHWPALWODJPQ-QNWVGRARSA-N canfosfamide Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 OJLHWPALWODJPQ-QNWVGRARSA-N 0.000 description 1
- 229950000772 canfosfamide Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
- 239000002804 dopamine agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004133 fatty acid degradation Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 201000010255 female reproductive organ cancer Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000001842 fibrogenetic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 1
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- MXDLFLPONIABIS-OLKYXYMISA-N kinamycin C Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(=[N+]=[N-])C1=C2[C@H](OC(=O)C)[C@@H](OC(C)=O)[C@](C)(O)[C@@H]1OC(C)=O MXDLFLPONIABIS-OLKYXYMISA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008299 phosphorodiamidates Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940001814 uvadex Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
- C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cytotoxic compounds and diagnostic imaging agents comprising HSP90-ligands and methods of use thereof are described.
Description
CYTOTOXINS AND DIAGNOSTIC IMAGING
RELATED APPLICATIONS
This application claims priority to Kamal et al., PCT/US02/39993, filed December 12, 2002, entitled ASSAYS AND IMPLEMENTS FOR DETERMINING
AND MODULATING HSP90 BINDING ACTIVITY, which claims priority to United States Provisional Patent Application Ser. No. 60/340,762, Eled December 12, 2001, and entitled ASSAYS FOR DETERMINING HSP90 BINDING ACTIVITY, each of which applications is herein incorporated by reference in its entirety.
FIELD OF INVENTION
The invention relates generally to assays for assessing ligand binding and binding affinity, and more specifically to heat shock protein 90 ("HSP90") binding assays.
BACKGROUND
The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed inventions, or that any publication specifically or implicitly referenced is prior art.
17-allylamino-geldanamycin (17-AAG) is a synthetic analog of geldanamycin (GDM). Both molecules belong to a broad class of antibiotic molecules known as ansamycins. GDM, as first isolated from the microorganism Streptomyces hygroscopicus, was originally identified as a potent inhibitor of certain kinases, and was later shown to act by stimulating kinase degradation, specifically by targeting "molecular chaperones," e.g., heat shock protein 90s (HSP90s). Subsequently, various other ansamycins have demonstrated more or less such activity, with 17-AAG
being among the most promising and the subject of intensive clinical studies currently being conducted by the National Cancer Institute (NCI). See, e.g., Federal Register, 66(129): 35443-35444; Erlichman et al., Proc. AACR (2001),42, abstract 4474.
HSP90s are ubiquitous chaperone proteins that are involved in folding, activation and assembly of a wide range of proteins, including key proteins involved in signal transduction, cell cycle control and transcriptional regulation.
Researchers have reported that HSP90 chaperone proteins are associated with important signaling proteins, such as steroid hornone receptors and protein kinases, including, e.g., Raf 1, EGFR, v-Src family kinases, Cdk4, and ErbB-2 (Buchner J., 1999, TIBBS, 24:136-141; Stepanova et al., 1996, Genes Dev. 10:1491-502; Dai, K. et al., 1996, J
Biol.
Chem, 271:22030-4).
Studies further indicate that certain co-chaperones, e.g., Hsp70, p60/Hop/Stil, Hip, Bagl, HSP40/Hdj2/Hsj 1, immunophilins, p23, and p50, may assist HSP90 in its function. See, e.g., Caplan, A., 1999, Trends in Cell Biol., 9: 262-68.
Ansamycin antibiotics, e.g., herbimycin A (HA), geldanamycin (GM), and 17-AAG are thought to exert their anticancerous effects by tight binding of the N-terminus pocket ofHSP90 (Stebbins, C. et al., 1997, Cell, 89:239-250). This pocket is highly conserved and has weak homology to the ATP-binding site of DNA gyrase (Stebbins, C. et al., supra; Grenert, J.P. et al., 1997, J. Biol. Chem., 272:23843-50).
Further, ATP and ADP have both been shown to bind this pocket with low affinity and to have weak ATPase activity (Proromou, C. et al., 1997, Cell, 90: 65-75;
Panaretou, B. et al., 1998, EMBO J., 17: 4829-36). In vitro and in vivo studies have demonstrated that occupancy of this N-terminal pocket by ansarnycins and other HSP90 inhibitors alters HSP90 function and inhibits protein folding. At high concentrations, ansamycins and other HSP90 inhibitors have been shown to prevent binding of protein substrates to HSP90 (Scheibel, T., H. et al., 1999, Proc.
Natl. Acad.
Sci. USA 96:1297-302; Schulte, T. W. et al., 1995, J. Bioi. Chern. 270:24585-8;
Whitesell, L., et al., 1994, Proc. Natl. Acad. Sci. USA, 91:8324-8328).
Ansamycins have also been demonstrated to inhibit the ATP-dependent release of chaperone-associated protein substrates (Schneider, c., L. et aL, 1996, Proc. Natl.
Acad. Sci.
USA, 93:14536-41; Sepp-Lorenzino et al., 1995, J Biol. Chem. 270:16580-16587).
In either event, the substrates are degraded by a ubiquitin-dependent process in the proteasome (Schneider, C., L., supra; Sepp-Lorenzino, L., et al., 1995, J.
Biol. Chem., 270:16580-16587; Whitesell, L. et al., 1994, Proc. Natl. Acad. Sci. USA, 91:
8328).
RELATED APPLICATIONS
This application claims priority to Kamal et al., PCT/US02/39993, filed December 12, 2002, entitled ASSAYS AND IMPLEMENTS FOR DETERMINING
AND MODULATING HSP90 BINDING ACTIVITY, which claims priority to United States Provisional Patent Application Ser. No. 60/340,762, Eled December 12, 2001, and entitled ASSAYS FOR DETERMINING HSP90 BINDING ACTIVITY, each of which applications is herein incorporated by reference in its entirety.
FIELD OF INVENTION
The invention relates generally to assays for assessing ligand binding and binding affinity, and more specifically to heat shock protein 90 ("HSP90") binding assays.
BACKGROUND
The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed inventions, or that any publication specifically or implicitly referenced is prior art.
17-allylamino-geldanamycin (17-AAG) is a synthetic analog of geldanamycin (GDM). Both molecules belong to a broad class of antibiotic molecules known as ansamycins. GDM, as first isolated from the microorganism Streptomyces hygroscopicus, was originally identified as a potent inhibitor of certain kinases, and was later shown to act by stimulating kinase degradation, specifically by targeting "molecular chaperones," e.g., heat shock protein 90s (HSP90s). Subsequently, various other ansamycins have demonstrated more or less such activity, with 17-AAG
being among the most promising and the subject of intensive clinical studies currently being conducted by the National Cancer Institute (NCI). See, e.g., Federal Register, 66(129): 35443-35444; Erlichman et al., Proc. AACR (2001),42, abstract 4474.
HSP90s are ubiquitous chaperone proteins that are involved in folding, activation and assembly of a wide range of proteins, including key proteins involved in signal transduction, cell cycle control and transcriptional regulation.
Researchers have reported that HSP90 chaperone proteins are associated with important signaling proteins, such as steroid hornone receptors and protein kinases, including, e.g., Raf 1, EGFR, v-Src family kinases, Cdk4, and ErbB-2 (Buchner J., 1999, TIBBS, 24:136-141; Stepanova et al., 1996, Genes Dev. 10:1491-502; Dai, K. et al., 1996, J
Biol.
Chem, 271:22030-4).
Studies further indicate that certain co-chaperones, e.g., Hsp70, p60/Hop/Stil, Hip, Bagl, HSP40/Hdj2/Hsj 1, immunophilins, p23, and p50, may assist HSP90 in its function. See, e.g., Caplan, A., 1999, Trends in Cell Biol., 9: 262-68.
Ansamycin antibiotics, e.g., herbimycin A (HA), geldanamycin (GM), and 17-AAG are thought to exert their anticancerous effects by tight binding of the N-terminus pocket ofHSP90 (Stebbins, C. et al., 1997, Cell, 89:239-250). This pocket is highly conserved and has weak homology to the ATP-binding site of DNA gyrase (Stebbins, C. et al., supra; Grenert, J.P. et al., 1997, J. Biol. Chem., 272:23843-50).
Further, ATP and ADP have both been shown to bind this pocket with low affinity and to have weak ATPase activity (Proromou, C. et al., 1997, Cell, 90: 65-75;
Panaretou, B. et al., 1998, EMBO J., 17: 4829-36). In vitro and in vivo studies have demonstrated that occupancy of this N-terminal pocket by ansarnycins and other HSP90 inhibitors alters HSP90 function and inhibits protein folding. At high concentrations, ansamycins and other HSP90 inhibitors have been shown to prevent binding of protein substrates to HSP90 (Scheibel, T., H. et al., 1999, Proc.
Natl. Acad.
Sci. USA 96:1297-302; Schulte, T. W. et al., 1995, J. Bioi. Chern. 270:24585-8;
Whitesell, L., et al., 1994, Proc. Natl. Acad. Sci. USA, 91:8324-8328).
Ansamycins have also been demonstrated to inhibit the ATP-dependent release of chaperone-associated protein substrates (Schneider, c., L. et aL, 1996, Proc. Natl.
Acad. Sci.
USA, 93:14536-41; Sepp-Lorenzino et al., 1995, J Biol. Chem. 270:16580-16587).
In either event, the substrates are degraded by a ubiquitin-dependent process in the proteasome (Schneider, C., L., supra; Sepp-Lorenzino, L., et al., 1995, J.
Biol. Chem., 270:16580-16587; Whitesell, L. et al., 1994, Proc. Natl. Acad. Sci. USA, 91:
8328).
This substrate destabilization occurs in tumor and non-transformed cells alike and has been shown to be especially effective on a subset of signaling regulators, e.g., Raf (Schulte, T. W. et ai., 1997, Biochem. Biophys. Res. Commun. 239:655-9;
Schulte, T. W., et al., 1995, J. Biol. Chem. 270:24585-8), nuclear steroid receptors (Segnitz, B:, arid U. Gehring. 1997, J. Biol. Chem, 272:18694-18701; Srnith, D. F. et al., 1995, Mol. Cell. Biol. 15:6804-12), v-src (Whitesell, L., et al., 1994, Proc. Natl.
Acad. Sci. USA, 91:8324-8328) and certain transmembrane tyrosine kinases (Sepp-Lorenzino, L. et al., 1995, J. Biol. Chem. 270:16580-16587) such as EGF
receptor (EGFR) and Her2/Neu (Hartmann, F., et al., 1997, Int. J. Cancer 70:221-9;
Miller, P.
et al., 1994, Cancer Res. 54:2724-2730; Mimnaugh, E. G., et al., 1996, J.
Biol. Chem.
271:22796-801; Schnur, R. et al., 1995, J. Med. Chem. 38:3806-3812), CDK4, and mutant p53. Erlichman et al., Proc. AACR (2001), 42, abstract 4474. The ansamycin-induced loss of these proteins leads to the selective disruption of certain regulatory pathways and results in growth arrest at specific phases of the cell cycle (Muise-Heimericks, R. C. et al., 1998, J Biol. Chem. 273 :29864-72), and apoptosis, and/or differentiation of cells so treated (Vasilevskaya, A. et al., 1999, Cancer Res., 59:3935-40). Ansamycins and HSP90 ligands in general thus hold great promise for the treatment and/or prevention of many types of cancers and proliferative disorders.
In addition to anti-cancer and antitumorgenic activity, IiSP90 inhibitors have also been implicated in a wide variety of other utilities, including use as anti-inflammation agents, anti-infectious disease agents, agents for treating autoimmunity, agents for treating ischernia, and agents useful in promoting nerve regeneration (See, e.g., Rosen et al., WO 02109696; PCT/USOI/23640; Degranco et al., WO 99/51223;
PCT/IJS99/07242; Gold, U.S. Patent 6,210,974 Bl). There are reports in the literature that fibrogenetic disorders including but not limited to scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis, and pulmonary fibrosis may be treatable. (Strehlow, WO 02/02123;
PCT/LTSOI/20578). Still further HSP90 modulation, modulators, and uses thereof are reported in PCT/LTS03/04283, PCT/US02/35938, PCT/LTS02/16287, PCT/US02/06518, PCT/US98/09805, PCT/US00/09512, PCT/USO1/09512, PCT/LTSOl/23640, PCT/LTSO1/46303, PCT/LTSOl/46304, PCT/LTS02/06518, PCT/LTS02/29715, PCT/US02/35069, PCT/LTS02/35938, PCT/US02/39993, PCTlUS03/10533, and PCT/US03/02686.
Schulte, T. W., et al., 1995, J. Biol. Chem. 270:24585-8), nuclear steroid receptors (Segnitz, B:, arid U. Gehring. 1997, J. Biol. Chem, 272:18694-18701; Srnith, D. F. et al., 1995, Mol. Cell. Biol. 15:6804-12), v-src (Whitesell, L., et al., 1994, Proc. Natl.
Acad. Sci. USA, 91:8324-8328) and certain transmembrane tyrosine kinases (Sepp-Lorenzino, L. et al., 1995, J. Biol. Chem. 270:16580-16587) such as EGF
receptor (EGFR) and Her2/Neu (Hartmann, F., et al., 1997, Int. J. Cancer 70:221-9;
Miller, P.
et al., 1994, Cancer Res. 54:2724-2730; Mimnaugh, E. G., et al., 1996, J.
Biol. Chem.
271:22796-801; Schnur, R. et al., 1995, J. Med. Chem. 38:3806-3812), CDK4, and mutant p53. Erlichman et al., Proc. AACR (2001), 42, abstract 4474. The ansamycin-induced loss of these proteins leads to the selective disruption of certain regulatory pathways and results in growth arrest at specific phases of the cell cycle (Muise-Heimericks, R. C. et al., 1998, J Biol. Chem. 273 :29864-72), and apoptosis, and/or differentiation of cells so treated (Vasilevskaya, A. et al., 1999, Cancer Res., 59:3935-40). Ansamycins and HSP90 ligands in general thus hold great promise for the treatment and/or prevention of many types of cancers and proliferative disorders.
In addition to anti-cancer and antitumorgenic activity, IiSP90 inhibitors have also been implicated in a wide variety of other utilities, including use as anti-inflammation agents, anti-infectious disease agents, agents for treating autoimmunity, agents for treating ischernia, and agents useful in promoting nerve regeneration (See, e.g., Rosen et al., WO 02109696; PCT/USOI/23640; Degranco et al., WO 99/51223;
PCT/IJS99/07242; Gold, U.S. Patent 6,210,974 Bl). There are reports in the literature that fibrogenetic disorders including but not limited to scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis, and pulmonary fibrosis may be treatable. (Strehlow, WO 02/02123;
PCT/LTSOI/20578). Still further HSP90 modulation, modulators, and uses thereof are reported in PCT/LTS03/04283, PCT/US02/35938, PCT/LTS02/16287, PCT/US02/06518, PCT/US98/09805, PCT/US00/09512, PCT/USO1/09512, PCT/LTSOl/23640, PCT/LTSO1/46303, PCT/LTSOl/46304, PCT/LTS02/06518, PCT/LTS02/29715, PCT/US02/35069, PCT/LTS02/35938, PCT/US02/39993, PCTlUS03/10533, and PCT/US03/02686.
Recently, Nicchitta et aL, WO 01/72779 (PCT/LTSOI/09512), demonstrated that HSP90 can assume a different conformation upon heat shock and/or binding by the fluorophore bis-ANS. Specifically, Nicchitta et al. demonstrated that this induced conformation exhibits a higher affinity for certain HSP90 ligands than another conformation that predominates in normal cells.
A fundamental step in identifying and evaluating HSP90 ligands is to be able to conveniently assay their binding affinity for HSP90. A variety of nonisotopic procedures, e.g., colorimetric, enzymatic, and densitometric, afford sufficient sensitivity in other contexts where they are preferred over isotopic procedures for health and disposal reasons, and Chiosis et al., Chemistry and Biology, 8:289-(2001), recently described a procedure for evaluating HSP90 ligand ability.
The Chiosis procedure, however, is cumbersome and time-consuming from the standpoint of requiring gels to be run, blotted, and probed with antibody. The Chiosis assay is further limited in its ability to conveniently support high-throughput screening.
Further, it appears that Chiosis employed a standard form of HSP90 that is characteristic of normal, healthy cells.
Needed are new diagnostic agents and therapies based on selective targeting of the HSP90 conformation that typifies cancerous, tumorous and infected cells.
SUMMARY OF THE INVENTION
The aspects and embodiments of the present invention build on those featured in PCT/US02/39993, which reported the identification of high-affinity conformations of HSP90 in cancer cells and uses thereof in HSP90 binding assays and HSP90 inhibitor identification. This application features the use of such high-affinity agents in vitro and/or in vivo to selectively target cells containing such high affinity forms for, on the one hand, diagnostic and prognostic assessment, and on the other hand for selective therapeutics and/or prophylactic protection against diseases and afflictions mediated and/or characterized by high affinity forms of HSP90. Applicants' report herein of the selective accumulation and persistence of HSP90 inhibitors in tumor and cancer cells relative to normal cells suggests that these agents will find excellent use as both diagnostic and therapeutic agents.
Thus, in a first aspect the invention features a diagnostic or cytotoxic composition having an HSP90 inhibitor functionalized with an additional moiety that affords imaging and/or cytotoxin properties. The HSP90 ligand preferably includes a member selected from the group consisting of purines, ansamycins, radicicol, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles. In some preferred embodiments, the inhibitor is a benzoquinoid ansamycin, preferably derivatized at position 17 with the cytotoxic and/or imaging agent/moiety. One embodiment for such a compound may be generically illustrated by the following formula, wherein X comprises the functional moiety, and wherein positions 4 and 5 are optionally both hydroxylated.
In some preferred embodiments, the functional moiety comprises a radioisotope/radionuclide, e.g., one selected from the group consisting of Iodenetzs, Iodenet3l, Technitium99m , Indiumltt, Rheniumt88, Gallium6~, Copper6~, Yttrium9o, and Astatine2l, ~aF, t tC, t3N, iz3h tz4h izsh t3lh zi3Bi and 150.; it is expected that these will find use not only as cytotoxic agents but also as imaging agents.
In other 1 S preferred embodiments, the functional moiety comprises a muslin or mustard-type molecule. Illustrative species of these two embodiments include compounds of formulas p I
0 ~
HN
HN ~ , ~zs ~HN I % ~ s NCI N
1 ~I~a 33~
Radionuclide moieties I I
Radjonuclide treatment ~
H HN
p ' N~N~CI ~ ~ ~ NCI
HN
/ ~~i F~a CI I
Radionuclide scanning (Positron Emission Tomography or PET) nitrogen mustard or "muslin"
Common isotopes are: 18F, 11C, 13N, 1231, 124) and 150 moieties In addition or as an alternative to the foregoing, the functional moieties of the invention may also include a member selected from the group consisting of antibodies, recombinant products, small molecules, antineoplastic agents, herceptin, taxol, taxanes and taxane derivatives, gleevec, alkylating agents, anti-rnetabilites;
epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor;
procarbazine;
mitoxantrone; platinum coordination complexes; biological response modifiers/growth inhibitors; hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors, anthracycline drugs, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, tepothilones, discodermolide, pteridine drugs, diynenes, podophyllotoxins, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin, podo-phyllotoxin derivatives, etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel, estramustine, carboplatin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT -11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.
In another aspect, the invention features a method of treating or preventing an HSP90-mediated disease by administering to a subject a pharmaceutically effective amount of a composition according to the preceding aspect and embodiments. The disease can be a neoplastic disease or one established of fostered by a pathogen, e.g., a virus, bacteria, or fungus. In some preferred embodiments, the disease is a cancer or tumor, preferably one selected from the group consisting of melanoma, breast, lung, or prostate cancer or tumor. In some embodiments, the diseased cells express supra-normal levels of Her-2 transcript, protein, or HSP90 client proteins. The treatment may be administered, e.g., orally, topically, subcutaneously, intramuscularly, intratumorally, parenterally or intravenously.
In some embodiments, the administration is made to removed tissues or cells of an organism (ex vivo). In other embodiments, the administration is made to the living organism itself (in vivo), which may entail an in situ administration directly to the site of a tumor and/or a general systemic administration. Preferably the subject is a mammal, more preferably a human. In some embodiments, the treatment is part of a chemotherapy regimen.
In another aspect, the invention features a method of diagnosing or monitoring the progression or regression of an HSP90-mediated disease by administering to the cells of a subject having or suspected of having an HSP90-mediated disease a composition according to the first aspect, and then evaluating those cells for the presence of underlying compound. Because the compound selectively accumulates and persists in diseased cells, it is easy to image such cells using, e.g., the well-known procedure of positron emission tornography (PET) or equivalent imaging technology.
The images created can, e.g., assist surgeons in identifying more precisely the location of turnorous or cancerous cells so as to excise or biopsy them. Alternatively, the imaging can be used to help diagnose disease or monitor its progression, regression, or the effect of treatment thereon. In the case of infectious diseases, normal cells and infected cells or tissues can be compared for the relative presence and/or concentration of the compounds of the invention as a measure of the disease state, or as a measure of therapy progress.
Additional advantages, aspects, and embodiments of the invention will be apparent from the figures, the detailed description, and claims to follow.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows competitive binding of geldanamycin and biotinylated geldanamycin for HSP90.
Figure 2 shows competitive binding of 17-allyl amino geldanamycin (17-AAG) and biotinylated geldanamycin for HSP90.
Figure 3 shows competitive binding of free geldanamycin, 17-AAG, and biotinylated geldanamycin for HSP90 .
Figure 4 shows that 17-AAG (CF7) has a higher apparent binding affinity for HSP90 from tumor cells (BT474) than normal cells (fibroblasts, RPTEC) or purified HSP90 alone, as determined using methods described herein.
Figure 5 shows that 17-AAG (CF7) has a higher apparent binding affinity fox HSP90 from the specific high Her2 expressing cells, SKOY-3, SKBR-3, and N87, than from normal cells, heat-shocked HSP90, or bis-ANS treated HSP90.
Figure 6 shows the results of various test compounds used in certain assay embodiments of the invention. The cell line used was MCF7. Synthesis and use of the modulators shown is described in PCT/US02129715.
Figure 7 shows the pharmacokinetic proftle of CF237 in a subcutaneous human tumor xenograft and in the liver and intestine of the host mice.
Figure 8 shows the pharmacokinetic proftle of CF237 in a subcutaneous human tumor xenograft and in the blood of the host mice.
Figure 9 shows the in vitro cellular drug uptake kinetics of CF237 in a human tumor breast tumor cell line and in normal human epithelial and endothelial cells.
DETAILED DESCRIPTION OF THE INVENTION
Definitions Compounds of the invention may embrace pharmaceutical salts of the underlying compounds. When a compound is named or displayed, it will be understood that pharmaceutically acceptable salts of such compound are also subsumed within the deftnition or structure.
A "pharmaceutically acceptable salt" may be prepared for any compound of the appropriate aspect of the invention having a functionality capable of forming a salt, for example an acid or base functionality. Pharmaceutically acceptable salts may be derived from organic or inorganic acids and bases. Compounds of the invention that contain one or more basic functional groups, e.g., amino or alkylamino, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable organic and inorganic acids. These salts can be prepared in situ during the Enal isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, malefic, phosphoric, glycolic, gluconic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic, 1,2 ethanesulfonic acid (edisylate), galactosyl-d-gluconic acid, and the like. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, may be employed in the preparation of pharmaceutically acceptable acid addition salts. See, e.g., Berge et al. "Pharmaceutical Salts", J. Pharm. Sci.
66:1-19 (1977).
Compounds of the present invention that contain one or more acidic functional groups are capable of forming pharmaceutically-acceptable salts with pharmaceutically- acceptable bases. The term "pharmaceutically-acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the.
hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically- acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
Illustrative examples of some of the bases that can be used include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, and the like. Representative organic amines useful for the formation of base addition salts include ethyl amine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. See, for example, Berge et al., supra.
A "pharmacological composition" refers to a mixture of one or more of the compounds described herein or pharmaceutically acceptable salts thereof, with other chemical components, such as pharmaceutically acceptable carriers and/or excipients.
The purpose of a pharmacological composition is to facilitate administration of a compound to an oxganism.
The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol arid polyethylene glycol; (12) esters, such as ethyl oleate and ethyllaurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water;
(17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. A physiologically acceptable carrier should not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
An "excipient" refers to an inert substance added to a pharmacological composition to further facilitate administration of a compound. Examples of excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
A "pharmaceutically effective amount" means an amount which is capable of providing a therapeutic and/or prophylactic effect. The specific dose of compound administered according to this invention to obtain therapeutic and/or prophylactic effect will, of course, be determined by the particular circumstances surrounding the case, including, for example, the specific compound administered, the route of administration, the condition being treated, and the individual being treated.
A typical daily dose (administered in single or divided doses) will contain a dosage level of from about 0.01 mg/kg to about 50-100 mg/kg of body weight of an active compound of the invention. Preferred daily doses generally will be from about 0.05 mg/kg to about 20 rng/kg and ideally from about 0.1 rnglkg to about 10 mg/kg. Factors such as clearance rate and half life and maximum tolerated dose (MTD) have yet to be determined but one of ordinary skill in the art can determine these using standard procedures.
In some method embodiments, the preferred therapeutic effect is the inhibition, to some extent, of the growth of cells characteristic of a proliferative disorder, e.g., breast cancer. A therapeutic effect will also normally, but need not, relieve to some extent one or more of the symptoms other than cell growth or size of cell mass. A therapeutic effect may include, for example, one or more of 1) a reduction in the number of cells; 2) a reduction in cell size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cell infiltration into peripheral organs, e.g., in the instance of cancer metastasis; 3) inhibition (i.e., slowing to some extent, preferably stopping) of tumor metastasis; 4) inhibition, to some extent, of cell growth;
and/or 5) relieving to some extent one or more of the symptoms associated with the disorder.
In some preferred embodiments of the invention, the "IC50" value of a compound of the invention is greater for normal cells than for cells exhibiting a proliferative disorder, e.g., breast cancer cells. The value depends on the assay used.
By a "standard" is meant a positive or negative control. A negative control in the context ofHER-2 expression levels is, e.g., a sample possessing an amount ofHER-2 protein that correlates with a normal cell. A negative control may also include a sample that contains no HER-2 protein. By contrast, a positive control does contain HER-2 protein, preferably of an amount that correlates with over-expression as found in proliferative disorders, e.g., breast cancers.. The controls may be from cell or tissue samples, or else contain purified ligand (or absent ligand), immobilized or otherwise. In some embodiments, one or more of the controls may be in the form of a diagnostic "dipstick."
By "selectively targeting" is meant affecting one type of cell to a greater extent than another, e.g., in the case of cells with high as opposed to relatively low or normal Her-2 levels.
HSP90 Li~ands HSP90 Iigands useful in the compositions and methods of the invention include, e.g., purines, ansamycins, radicicol, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles, which compounds are well-known in the art.
Preferred are ansamycins, which are known to inhibit HSP90 function. The term "ansamycin" as used herein is well-known in the art and refers to a broad class of structures characterized by aliphatic rings of various length and constitution bridging opposite ends of aromatic ring structures and their reduced equivalents.
Subsumed within this broad class is the sub-class, benzoquinone ansamycins. A
"benzoquinone ansamycinin" as used herein possesses a benzoquinone as the aromatic ring structure and includes any benzoquinone ansamycin known in the art having an alkoxy moiety on the benzoquinone portion of the molecule, preferably a methoxy, and preferably at the 17 position, that can be replaced by a nucleophile. The result of the reaction is the formation of a "benzoquinone ansamycin derivative." Ansarnycins further include dimers and pharmaceutically acceptable salts of the ansamyin compound.
Ansamycins may be synthetic, naturally-occurring, or a combination of the two, i.e., "semi-synthetic." Exemplary ansamycins useful in the processes of the invention and their methods of preparation include but are not limited to those described, e.g., in U.S. Patents 3,595,955 (describing the preparation of geldanamycin), 4,261,989, 5,387,584, and 5,932,566. Geldanamycin is also commercially available, e.g., from CN Biosciences, an affiliate of Merck headquartered in San Diego, California, USA
(cat. no. 345805). The biochemical purification of 4,5-Dihydrogeldanamycin and its hydroquinone from cultures of Streptomyces hygroscopicus (ATCC 55256) are described Cullen et al. in International Application Number PCT/US92/10189 (WO
93/14215), assigned to Pfizer Inc. An alternative method of synthesis for 4,5-Dihydrogeldanamycin by catalytic hydrogenation of geldanamycin is also known.
See, e.g., Progress in the Chemistry of Organic Natural Products, Chemistry a/the Ansamycin Antibiotics, 33 1976, p. 278. Applicants recently described the preparation of numerous other ansamycin compounds in commonly owned co-pending applications PCT/LJS03/04283 and PCT/LJS02/29715, including the dimer CF237 which appears in one of the examples below.
HSP90s HSP90 proteins are ubiquitous cellular proteins that are highly conserved in nature. The term "an HSP90" or "an HSP90 member" as claimed herein includes but is not limited to the following: NCBI accession #'s P07900 and XM 004515 (human a and ~3 HSP90 respectively), P11499 (mouse), AAB2369 (rat), P46633 (chinese hamster), JC1468 (chicken), AAF69019 (flesh fly), AAC21566 (zebrafish), AAD30275 (salmon), 002075 (pig), NP 015084 (yeast), and CAC29071 (frog).
Further included in the definition are any variations of such proteins that may exist in nature or that are man- made. All are expected to have more or less utility in connection with the methods, assays, and ligands of the invention, e.g., in identifying and/or quantifying binding affinities of various HSP90 ligands, and thereby identifying andlor prioritizing new drug candidates for clinical trials. One aspect of the invention exploits Applicants' finding that cancer and tumor cells possess a more sensitive, high affinity, form of HSP90s than do normal cells. Ligands bind HSP90s found in cancer or tumor cells much more avidly despite the protein itself having an identical amino acid constituency. Without being limiting of the invention, this is thought to be a consequence of a different tertiary or quarternary configuration of the protein that is present in such cells, possibly being afforded by co-chaperone proteins or client proteins that are bound to the HSP90 to make it behave as such.
The following discussion sections concerning labeling and solid supports and high throughput screening are borrowed largely from United States Patents 6,203,989, 6,153,442, 6,096,508, 5,846,537, and 5,585,241. The procedures described therein and below can be assimilated, adapted, and/or otherwise implemented in furtherance of the novel and unobvious features of the present invention.
Labels and Labeling The following discussion sections concerning labeling and solid supports and high throughput screening are borrowed largely from United States Patents 6,203,989, 6,153,442, 6,096,508, 5,846,537, and 5,585,241. The procedures described therein and below can be assimilated, adapted, and/or otherwise implemented in furtherance of the novel and unobvious features of various aspects and embodiments of the present invention.
Biotin:(Strept)Avidin Labels. Some preferred embodiments of the invention exploit the natural high affinity of streptavidin for biotin. Streptavidin is related to avidin, a 67 kilodalton (kD) glycoprotein found in e~g whites and which has an exceptionally high binding affinity (Kd =l0-15 M) for biotin. Avidin consists of four subunits, each capable of binding one biotin molecule.
Streptavidin is produced by Streptomyces avidihii and shares significant conformation and amino acid composition with avidin, as well as high affinity for biotin and stability.
Streptavidin is also not glycosylated and reportedly exhibits less non-specific binding than avidin, making it the superior choice of the two for most biotin-based applications.
Biotin, a member of the B-complex vitamins, is found naturally and is essential for amino acid and fatty acid degradation, gluconeogenesis, and fatty acid synthesis. The binding interactions between biotin and the biotin binding site of avidin and streptavidin are the result of non covalent hydrogen bonding and van der Waals interactions between biotin and avidin, together with the ordering of surface polypeptide loops that bury the biotin in the protein interior. Biotin has previously been chemically or enzyrnatically coupled extensively to probe biomolecules in ways that minimize interference with target recognition, and the results described herein for geldanamycin provide further examples of how this may be done.
Reagents for labeling streptavidin or avidin with a fluorescent tag are commercially available. For example, the reagents, 5(6)-Carboxyfluorescein-N-hydroxysuccinirnide ester (FLUOS), 7-amino-4-methyl-coumarin-3-acetic acid-N'-hydroxysuccinimide ester (AMCA, activated) and fluorescein isothiocyanate (FITC) are available from Boehringer Mannheim, Indianapolis, Ind., USA. Methods for fluorescently labeling proteins with fluorescent labels, and methods for detection of the fluorescent labels, are described in Howard, G., Labeling Proteins with Fluorochromes, in "Methods in Nonradioactive Detection,", G, Howard; Ed., Appleton and Lange, Norwalk, Conn, USA. 1993, pp. 39-6~, the disclosure of which is incorporated herein. Additionally, there are a variety of commercially available streptavidin- and avidin-labeled molecules. Examples include streptavidin-gold, streptavidin-fluorochrorne, streptavidin-AMCA, streptavidin- fluorescein, streptavidin-phycoerythrin (STPE), streptavidin-sulforhodamine 101, avidin-FITC
and avidin-Texas red.RTM:, which are commercially available from Boehringer Mannheim, Indianapolis, Ind., USA. A working example of the use of streptavidin-phycoerythrin in the methods and reagents of some aspects and embodiments of the invention is described below.
In addition to the biotin-steptavidin system described above, other labels or label complexes can also be used to generate a detectable signal to relate the amount of bound and/or unbound label. The label can be any molecule that produces or can be induced to produce a signal, and may be, for example, a fluoresces, radio-label, enzyme, dense element such as gold, chemiluminescer or photosensitizes. Thus, the signal, depending on the label embodiment, can be detected and/or measured by detecting enzyme activity, luminescence, light absorbance or radioactivity as the case may be. In some applications, nonradioactive applications are preferred.
Specific labels that can be used illustratively include, e.g., enzymes such as alkaline phosphatase, glucose-6-phosphate dehydrogenase ("G6PDH") and horseradish peroxidase;.dyes; fluorescers such as fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, and fluorescamine; chemiluminescers such as isoluminol; sensitizers; coenzymes;
enzyme substrates; radiolabels such as 125 I, l31 I, l4 C, 3 H, 57 Co and 75 Se; panicles such as latex, or carbon particles; metals;
crystallite;
liposomes; cells, photoactivatable compounds etc., which may be further labeled with a dye, catalyst or other detectable group. Other suitable enzymes and coenzymes are disclosed in Litman, et al., U.S. Pat. No. 4,275,149, columns 19-28, and Boguslaski, et al., U.S. Pat. No. 4,318,980, columns 10-14. Suitable fluorescers and chemiluminescers are disclosed in Litman, et al., U.S. Pat. No. 4,275,149, at columns 30 and 31. Photoactivatable compounds include but are not limited to those containing reactive enediyne and terminal diazo groups, e.g., the natural products Dynemicin, Kinamycin C, and Prekinamycin, as disclosed at http~//www Indiana edu/~zale~rt~/overview acs.html. Others include, e.g., UVADEX
and Methoxypsoralen (8-MOP) that are reported efficacious in extracorporeal photochemotherapy (ECP), as well as TER286 [g-glutarnyl-a-amino-b(2-ethyl-N,N,N',N'-tetrakis (2-chloroethyl) phos-phorodiamidate)-sulfonyl)-propionyl-(R)-(-) phenylglycine] (a nitrogen mustard prodrug) and 35S]-azidophenacyl-glutathione ([35S]APA-SG), chlorins, porphyrins, and phthalocyanines. See, e.g., htt~:l/www.ibmtindy.com./faq/photopheresis.htm;
htty//www fccc.edu/research/reports/current/tew.repoutframe.html http ~//www.info.med.yale.eduldermatolo~/clinical/nhoto.html;
http~/lsearch msn.com/results.asp?FORM=sCPN&RS=C:HECKED&un=doc~v=1&~
~hotoactivatable°1o20dru~; Qualls et al., "Synergistic Phototoxicity of Chloroaluminum Phthalocyanine Tetrasulfonate Delivered via Acid-Labile Diplasmenylcholine-Folate Liposomes", International Journal of Cancer 2001, 93, 384-392. Each of the preceding is herein incorporated by reference.
The label used may directly produce a signal. Alternatively, the label may indirectly produce a signal and therefore require additional reagents and/or physical stimulation, e.g., bombardment with electromagnetic energy or the addition of a chemical substrate or co-factor. In the instance of fluorescers, for example, these are able to absorb ultraviolet and visible light where the light absorption transfers energy to these molecules and elevates them to an excited energy state, which absorbed energy is then dissipated by emission of light at a second wavelength. By contrast, labels that directly produce a signal include, e.g., radioactive isotopes and dyes.
Examples of labels that need other reagent components to produce a Signal include, e.g., substrates and coenzymes (for enzyme labels), substances that react with enzymic products, catalysts, activators, cofactors, inhibitors, scavengers, metal ions, and a specific binding substance required for binding of signal generating substances.
Additional discussion of suitable labeling systems can be found, e.g., in Ullrnan, et al., U.S. Pat. 5,155,243, columns 11-13, the disclosure of which is herein incorporated by reference.
The assay methods of the invention may be conveniently performed on a solid support, such as in multi-well plates for an ELISA or on any solid support for high density or chip array analysis, for example, in an ELISA type format, the ligand or receptor molecule is adsorbed to a solid support such as the wells of a 96-well plate.
The corresponding complement (receptor or ligand, whichever the case may be), is/are added to the wells and incubated. Alternatively, the complexes may first be formed and then adhered to the solid support, to be competed with later by another ligand or compound of interest. In yet another embodiment, multiple ligands, at least one of which is known and labeled, are mixed together in the presence of an and, by whichever of a broad variety of means known in the art, noncomplexed and nonadhered species (in solid support embodiments) are removed. The amount of label is then assessed using a detection device. Removal of noncomplexed and nonadhered species can be done by wash steps, and in some embodiments, centrifugation.
Unbound ligand/receptor is washed away and the presence of labeled complex is then detected. Many variations are possible.
Detection hardware devices that can be used in connection with various embodiments of the present invention are well known in the art and include but are not limited to, e.g., densitometers, mass spectrometers, fluorometers, scintillation counters, spectrophotometers, nrnr devices, positron emission tomography (PET) devices, luminometers, cameras, and other imaging or detection devices. These devices and their use are all well known in the art. For example, PET is described in Mandelkern et al., Positron enaission tonaography in cancer research and treatment.
Technologies in Cancer Research and Treatment (2002) 1(6):423-39, and Zimny et al., Positron emission tomography scanning in gynecologic and breast cancers, Current Opinion in Obstetrics and Gynecology. (2003) 15(1):69-75.
Assays to Determine HSP90 Binding and Downstream Effect .
In addition to the innovations described herein, a variety of in vitro and in vivo assays are available to test the effect of the compounds of the invention on HSP90.
HSP90 competitive binding assays and functional assays can be performed as known in the art substituting in the compounds of the invention. Chiosis et al., Chemistry &
Biology 8:289-299 (2001 ) describe some of the known ways in which this can be done. For example, competition binding assays using, e.g., geldanamycin or 17-AAG
as a competitive binding inhibitor ofHSP90 can be used to determine relative affinity of the compounds of the invention by immobilizing the compound of interest or other competitive inhibitor on a gel or solid matrix, preincubating HSP90 with the other inhibitor, passing the preincubated mix over the gel or matrix, and then measuring the amount of HSP90 that sticks or does not stick to the gel or matrix.
Downstream effects can also be evaluated based on the known effect ofHSP90 inhibition on function and stability of various steroid receptors and signaling proteins including, e.g., Rafl and Her2. Compounds of the present invention induce dose-dependent degradation of these molecules, which can be measured using standard techniques. Inhibition of HSP90 also results in up-regulation of HSP90 and related chaperone proteins that can similarly be measured. Antiproliferative activity on various cancer cell lines can also be measured, as can morphological and functional differentiation related to HSP90 inhibition.
Many different types of methods are known in the art for determining protein concentrations and measuring or predicting the level of proteins within cells and in fluid samples. Indirect techniques include nucleic acid hybridization and amplification using, e.g., polymerase chain reaction (PCR). These techniques are known to the person of skill and are discussed, e.g., in Sarnbrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, NY, 1994, and, as specifically applied to the quantification, detection, and relative activity of Her-2/neu in patient samples, e.g., in U.S. Patents 4,699,877, 4,918,162, 4,968,603; and 5,846,749. A brief discussion of two generic techniques that can be used follows.
The determination of whether cells over-express or contain elevated levels of HER- 2 can be determined using well known antibody techniques such as immunoblotting, radioimmunoassays, western blotting, iminunoprecipitation, enzyme-linked immunosorbant assays (ELISA), and derivative techniques that make use of antibodies directed against HER-2. As an example, HER-2 expression in breast cancer cells can be determined with the use of an immunohistochernical assay, such as the Dako HercepTM test (Dako Corp., Carpinteria, CA). The HercepTM test is an antibody staining assay designed to detect HER-2 over-expression in tumor tissue specimens. This particular assay grades HER-2 expression into four levels: 0, l, 2, and 3, with level 3 representing the highest level of HER-2 expression.
Accurate quantitation can be enhanced by employing an Automated Cellular Imaging System (ACIS) as described, e.g., by Press, M, et al. , 2000, Modern Pathology, 13:225A.
Antibodies, polyclonal or monoclonal, can be purchased from a variety of commercial suppliers, or may be manufactured using well-known methods, e.g., as described in Harlow et al" Antibodies: A Laboratory Manual, 2nd Ed; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1988).
HER-2 over-expression can also be determined at the nucleic acid level since there is a reported high correlation between over-expression of the HER-2 protein and amplification of the gene that codes for it. One way to test this is by using RT - PCR.
The genomic and cDNA sequences for HER-2 are known. Specific DNA primers can be generated using standard, well-known techniques, and can then be used to amplify template already present in the cell. An example of this is described in Kurokawa, H.
et al., Cancer Res. 60: 5887-5894 (2000). PCR can be standardized such that quantitative differences are observed as between normal and abnormal cells, e.g., cancerous and noncancerous cells. Well known methods employing, e.g., densitometry, can be used to quantitate and/or compare nucleic acid levels amplified using PCR.
Similarly, fluorescent in situ hybridization (FISH) assays and other assays can be used, e.g., Northern and/or Southern blotting. These rely on nucleic acid hybridization between the HER-2 gene or mRNA and a corresponding nucleic acid probe that can be designed in the same or a similar way as for PCR primers, above.
See, e.g., Mitchell, MS, and Press, MF, 1999, Semin. Oncol., Suppl. 12:108-16.
For FISH, this nucleic acid probe can be conjugated to a fluorescent molecule, e.g., fluorescein andlor rhodamine, that preferably does not interfere with hybridization, and which fluorescence can later be measured following hybridization. See, e.g., Kurokawa, H et al., Cancer Res. 60: 5887- 5894 (2000) (describing a specific nucleic acid probe having sequence 5'-FAM- NucleicAcid-TAMRA-p-3' sequence). ACIS-based approaches as described above can be employed to make the assay more quantitative (de la Torre-Bueno, J, et al , 2000, Modem Pathology 13:221A).
Immuno and nucleic acid detection can also be directed against proteins other than HSP90 and Her-2, which proteins are nevertheless affected in response to inhibition.
Pharmaceutical Compositions, Dosa~in~ and Modes of Administration Compounds identified as promising using the assays of the invention can in turn be formulated into pharmaceutical compositions and then administered to subj ects.
Those of ordinary skill in the art are familiar with formulation and administration techniques that can be employed with the compounds and methods of the invention, e.g., as discussed in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition; Pergamon Press; and Remington Pharmaceutical Sciences (current edition.), Mack Publishing Co., Easton, Pa., USA.
The compounds utilized in the methods of the instant invention may be administered either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharniaceutical practice. The compounds can be administered orally or parenterally, are nevertheless affected in response to HSP90 including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
For example, the therapeutic or pharmaceutical compositions of the invention can be administered locally to the area in need of treatment. This may be achieved by, for example, but not limited to, local infusion during surgery, topical application, e.g., cream, ointment, injection, catheter, or implant, said implant made, e.g., out of a porous, non- porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. The administration can also be by direct injection at the site (or former site) of a tumor or neoplastic or pre-neoplastic tissue.
Still further, the compounds or compositions of the invention can be delivered in a vesicle, e.g., a liposome (see, for example, Langer, 1990, Science, 249:1527-1533; Treat et al., 1989, Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Bernstein and Fidler (Eds.), Liss, N.Y., USA, pp. 353-365).
The compounds and pharmaceutical compositions used in the methods of the present invention can also be delivered in a controlled release system. In one embodiment, a pump may be used (see, Sefton, 1987, CRC Grit. Ref. Biomed. Eng.
14:201; Buchwald et al., 1980, Surgery, 88:507; Saudek et al., 1989, N. Eng.
J. Med., 321:574). Additionally, a controlled release system can be placed in proximity of the therapeutic target (see, e.g., Goodson, 1984, Medical Applications of Controlled Release, Vol. 2, pp. 115-138).
The pharmaceutical compositions used in the methods of the instant invention can also contain the active ingredient in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according-to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as microcrystalline cellulose;
sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be un-coated or coated by known techniques to mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a water soluble taste masking material such as hydroxypropylrnethyl-cellulose or hydroxypropylcellulose, or a time delay material such as ethyl cellulose, or cellulose acetate butyrate may be employed as appropriate.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl cellulose, methylcellulose, hydroxypropylrnethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol aziliydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti=oxidant such as ascorbic acid.
The compounds and pharmaceutical compositions used in the methods of the instant invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be natural ly-occurnng phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening agents, flavoring agents, preservatives and antioxidants.
Syrups and elixirs may be formulated with sweetening agents, e.g., glycerol, propylene glycol: sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
The pharmaceutical compositions may be in the form of sterile injectable aqueous solutions. Acceptable vehicles and solvents that may include, e.g., water, Ringer's solution and isotonic sodium chloride solution.
The sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For example, the active ingredient may be first dissolved in a mixture of soybean oil and lecithin. The oil solution is then introduced into a water and glycerol mixture and processed to form a micro emulsion.
The injectable solutions or micro emulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous to administer the solution or micro emulsion in such a way as to maintain a constant circulating concentration of the instant compound. In order to maintain such a constant concentration, a continuous intravenous delivery device may be utilized. An example of such a device is the Deltec CADD-PLUSTM model 5400 intravenous pump.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration.
This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3- butane dial. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The Compounds of the present invention used in the methods of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the inhibitors with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing a compound or composition of the invention can be used. As used herein, topical application can include, e.g., mouth washes and gargles.
The compounds used in the methods of the present invention can be administered in intianasal form via topical use of suitable intranasal vehicles and delivery devices, or via trans dermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
The methods, compounds and compositions of the instant invention may also be used in conjunction with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated. For example, the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents. Further, the instant methods and compounds may also be useful in combination with other inhibitors of parts of the signaling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation.
The methods of the present invention may also be useful with other agents that inhibit angiogenesis and thereby inhibit the growth and invasiveness of tumor cells, including, but not limited to VEGF receptor inhibitors, including ribozymes and antisense targeted to VEGF receptors. angiostatin and endostatin.
Examples of antineoplastic agents that can be used in combination with the compounds and methods of the present invention include, in general, and as appropriate, alkylating agents, anti-metabolites; epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes; biological response modifiers and growth inhibitors;
hormonallanti-hormonal therapeutic agents and haematopoietic growth factors.
Exemplary classes of antineoplastics include theanthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the epothilones, discodermolide, the pteridine family of drugs, diynenes and the podophyllotoxins. Particularly useful members of those classes include, for example, carminomycin,. daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podo-phyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel and the like. Other useful antineoplastic agents include estramustine, carboplatin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-II, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.
When a compound or composition of the invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for cancer, for example, breast cancer.
Administration typically occurs in an amount of between about 0.01 mg/kg of body weight to about 100 mg/kg of body weight per day (administered in single or divided doses), more preferably at least about 0.1 mg/kg of body weight per day. A
particular therapeutic dosage can include, e.g., from about 0.01 mg to about 1000 mg of compound, and preferably includes, e.g., from about 1 mg to about 1000 mg. The quantity of active compound in a unit of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, preferably from about 1 mg to 300 mg, more preferably mg to 200 mg, according to the particular application. The amount administered will vary depending on the particular IC50 value of the compound used and the judgment of the attending clinician taking into consideration factors such as health, weight, and age. In combinational applications in which the compound is not the sole active ingredient, it may be possible to administer lesser amounts of compound and still have therapeutic or prophylactic effect.
Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art.
Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small amounts until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
The amount and frequency of administration of the compounds and compositions of the present invention used in the methods of the present invention, and if applicable other chemotherapeutic agents and/or radiation therapy, will be regulated according to the judgment of the attending clinician (physician) considering such factors as age, condition and size of the patient as well as severity of the disease being treated.
The chemotherapeutic agent and/or radiation therapy can be administered according to therapeutic protocols well known in the art. It will be apparent to those skilled in the art that the administration of the chemotherapeutic agent andlor radiation therapy can be varied depending on the disease being treated and the known effects of the chemotherapeutic agent andlor radiation therapy on that disease. Also, in accordance with the knowledge of the skilled clinician, the therapeutic protocols (e.g., dosage amounts and times of administration) can be varied in view of the observed effects of the administered therapeutic agents (i.e., antineoplastic agent or radiation) on the patient, and in view of the observed responses of the disease to the administered therapeutic agents.
Also, in general, the compounds of the invention need not be administered in the same pharmaceutical composition as a chemotherapeutic agent, and may, because of different physical and chemical characteristics, be administered by a different route. For example, the compounds/compositions may be administered orally to generate and maintain good blood levels thereof, while the chemotherapeutic agent may be administered intravenously. The determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the skilled clinician. The initial administration can be made according to established protocols known in the art, and then, based upon the observed.
The particular choice of compound (and where appropriate, chemotherapeutic agent and/or radiation) will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol.
The compounds/compositions of the invention (and where appropriate chemotherapeutic agent andlor radiation) may be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the proliferative disease, the condition of the patient, and the actual choice of chemothexapeutic agent and/or radiation to be administered in conjunction (i.e., within a single treatment protocol) with the compound/cornposition.
In combinational applications and uses, the compound/composition and the chemotherapeutic agent and/or radiation axe not administered simultaneously or essentially simultaneously, then the initial order of administration of the compound/composition, and the chemotherapeutic agent and/or radiation, may not be important. Thus, the compounds/compositions of the invention may be administered first followed by the administration of the chemotherapeutic agent and/or radiation; or the chernotherapeutic agent and/or radiation may be administered first followed by the administration of the compounds/compositions of the invention. This alternate administration may be repeated during a single treatment protocol. The determination of the order of administration, and the number of repetitions of administration of each therapeutic agent during a treatment protocol, is well within the knowledge of the skilled physician after evaluation of the disease being treated and the condition of the patient. For example, the chemotherapeutic agent andlor radiation may be administered first, especially if it is a cytotoxic agent, and then the treatment continued with the administration of the compounds/cornpositions of the invention followed, where determined advantageous, by the administration of the chemotherapeutic agent and/or radiation, and so on until the treatment protocol is complete.
Thus, in accordance with experience and knowledge, the practicing physician can modify each protocol for the administration of a eompound/composition for treatment according to the individual patient's needs, as the treatment proceeds.
The attending clinician, in judging whether treatment is effective at the dosage administered, will consider the general well-being of the patient as well as more definite signs such as relief of disease-related symptoms, inhibition of tumor growth, actual shrinkage of the tumor, or inhibition of metastasis. Size of the tumor can be measured by standard methods such as radiological studies, e.g., CAT or MRI
scan, and successive measurements can be used to judge whether or not growth of the tumor has been retarded or even reversed. Relief of disease-related symptoms such as pain, and improvement in overall condition can also be used to help evaluate treatment efficacy.
EXAMPLES
The following examples are offered by way of illustration only and not by way of limitation. Examples 1-3 illustrate alternative methods ofproducing a biotinylated geldanamycin, of formulalcompound 5. Example 4 illustrates that such a compound is useful in competitive binding assays with other HSP90 ligands, e.g., other ansamycins such as geldanamycin and 17-AAG. Example 5 illustrates how HSP90s taken from tumor cell lines more avidly bind known HSP90 ligands. Example 6 demonstrates the selective accumulation and persistence of CF237 (an ansamycin dimer) in mouse and human tumors. Example 7 illustrates prophetic examples of preparing radionuclide-functionalized or cytotoxin-functionalized geldanamycin derivatives.
Example 1: Synthesis of biotinylated ansamycins useful for competition binding studies with HSP90.
This example follows the scheme:
NON /v I I N
O °H ~O
S N'/~0~~O'/~'N
O ~ _ NON
O
N~ ~O~
THF S o ° NH I I °
--~ ~ ~N -~' I
RT '~~'' ° off ~o 3 o w o -wherein the compound numbers are denoted beneath the corresponding structures;
and wherein the details of the synthesis are as follows.
To 50 mg (0.134 mmol) of (+)-biotinyl-3,6-dioxaoctanediamine 1 in 3 mL of 15:1 THF-H20 was added 29.9 (0.053 mmol) of geldanamycin 2 at room temperature.
The reaction was stirred overnight, quenched with water (50 mL) and extracted with 2 x 50 mL of EtOAc. The EtOAc extracts were combined, washed with 2 x 50 mL of H20, 1 x 50 mL of brine, dried (MgS04) and purified by silica gel flash chromatography to give 88 mg (0.095 mmol) in 71 %yield of 3. MP 113-117 °C: MS
926 (M + Na).
Example 2: Synthesis of biotinylated ansamycins useful for competition binding studies with HSP90.
This example follows the scheme:
,o o I I o NON N i V
N~NH2 ~ ~ O OH 'O
S O ~ O
O I
Z H~o N~'N
H O
THF _~S~ o NON I I o ~'N ~~I
RT .~~'' o off 'o o '. o I
- NH~O
wherein the compound numbers are denoted beneath the corresponding structures, and wherein the details of the synthesis are as follows.
To 50 mg (0.152 mmol) of 5-(biotinamido)pentylamine 4 in 3 mL of 15:1 THF-H20 was added 28 mg (0.050 mmol) of geldanamycin 2 at room temperature.
The reaction was stirred overnight, quenched with water (50 mL) and extracted with 2 x 50 mL of EtOAc. The EtOAc extracts were combined, washed with 2 x 50 mL of H20, 1 x 50 mL of brine, dried (MgS04) and purified by silica gel flash chromatography to give 100 rng (0.114 mmol) of 5 in 75 % yield. MP 143-147 °C.
MS 880 (M + Na).
Example 3: Synthesis of biotinylated ansamycins useful for competition binding studies with HSP90.
This example follows the scheme:
o I I
NON N ~ I
~~~"~ O OHH ~~
-~N~..O~O~O~NHz O . ~ O
O t 6 2 = Hz o TNF
RT
wherein the compound numbers are denoted beneath the corresponding structures and the details of the synthesis are as follows.
To 50 mg (0.119 rnmol) of (+)-biotinyl-3,6,9-trioxaundecanediamine 6 in 3 mL of 15:1 THF-H20 was added 26.8 mg (0.048 mmol) of geldanamycin 2 at room temperature. The reaction was stirred overnight, quenched with water (50 mL) and extracted with 2 x 50 mL of EtOAc. The EtOAc extracts were combined, washed with 2 x 50 mL of H20, 1 x 50 mL of brine, dried (MgS04) and purified by silica gel flash chromatography to give 84 mg (0.087 mmol) of 7 in 73°!° yield.
MP 103-104 °C. MS
970 (M + Na).
Example 4: HSP90 Binding Assay Utilizing A Biotinylated Ansamycin Purified native HSP90 protein was coated onto 96-well plates by incubating for 1 hr. at 37°C. Uncoated HSP90 was removed and the wells washed twice in 1 x PBS (phosphate-buffered saline) buffer. Compound 5 (biotinylated geldanamycin) was then added to the wells, and the reaction was further incubated for lhr at 37°C.
The wells were washed twice with 1 x PBS, before the addition of 20ug/ml streptavidin-phycoerythrin, and incubated for lhr at 37°C. The wells were again washed twice with 1 x PBS. The fluorescence was then measured in a Gemini Spectrofluorometer (Molecular Devices Corp, Sunnyvale, CA, USA) using.an excitation of 485nm and emission of 580 nm.
Figures 1-3 show assay embodiments employing different HSP90 ligands.
Details of the assays are as follows:
Figure 1. Competition of biotinylated-GM (compound S) binding by free geldanamycin (GM). Native HSP90 that was coated onto 96-well plates was pre-incubated with increasing concentrations of 0 nM (B3), 100 nM(C3), 300 nM
(D3), 1000 nM (E3), 3000 nM (F3), 10,000 nM (G3), and 100,000nM (closed diamonds) of geldanamycin and then S was added. Binding of S was detected by measuring the fluorescence of streptavidin-phycoerythrin (excitation: 48S run; emission: 510-run). The background fluorescence without any HSP90 present (A3) was minimal.
Increasing concentrations of GM inhibits the peak fluorescence at 580 run.
Figure 2. Competition of biotinylated-GM (compound 5) binding by 17 -allyl amino geldanamycin (17-AAG). Native Hsp90 that was coated onto 96-well plates was pre-incubated with increasing concentrations of 0 nM (B4), 100 nM (C4), nM (D4), 1000 nM (E4), 3000 nM (F4), 10,000 nM (G4), and 100,000 nM (closed diamonds) of 17-AAG and then 5 was added. Binding of 5 was detected by measuring the fluorescence of streptavidin-phycoerythrin (excitation: 48Snm;
1 S emission: 510-650 nm). The background fluorescence without any HSP90 present (A4) was minimal. Increasing concentrations of 17-AAG inhibits-the peak fluorescence at 580 nm Figure 3. Competition ofbiotinylated-GM (compound 5) binding by geldanamyein (GM) and 17-allyl amino geldanamycin (17-AAG). Native Hsp90 that was coated onto 96-well plates was pre-intubated, with increasing concentrations of 0-100,000 nM of either GM or 17 -AAG and then S was added Binding of S was detected by measuring the fluorescence of streptavidin-phycoerythrin (excitation: 485 nm; emission: 580 nm). The background fluorescence without any HSP90 present was minimal. Increasing concentrations of GM or 17 -AAG inhibits the peak fluorescence 2S at 580 nm.
Example 5: HSP90s taken from tumor cell lines more avidly bind HSP90 ligands Purified native HSP90 protein (Stressgen) or cell lysates prepared in lysis buffer (20mM Hepes, pH 7.3, 1 mM EDTA, SmM MgCl2, lOOmM I~Cl) wexe incubated in the absence or presence of CF7 (17-AAG) or test compound for 1 Smin at 4°C. Biotin- geldanarnycin (biotin-GM) was then added to the mixture as discussed previously, and the reaction was further incubated by rotating for lhr at 4°C. ' BioMagTM streptavidin magnetic beads were then added to the mixture, and the reaction was incubated by rotating for another lhr at 4°C. Tubes were placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads were washed three times in lysis buffer, and the washes discarded. SDS-PAGE sample buffer was added to the beads and boiled for 5 min at 95°C. Samples were analyzed on 10% SDS protein gels (Novex), and then Western blots using anti-HSP90 monoclonal antibody (Stressgen SPA-830). The bands in the Western Blots were quantitated using the Bio-rad Fluor-S Imager, and the % inhibition of binding of CF7 or test compound calculated. The IC50 reported is the concentration of the compound needed to cause half maximal inhibition of binding. For experiments that utilized shocked HSP90, the purified HSP90 native protein was incubated for 15 min at 90°C.
For experiments that utilized bis-ANS treated HSP90, the purified HSP90 protein was incubated with bis-ANS (Molecular Probes) for 30 min at 37°C. The results are shown in Figures 4-6.
Example 6: Pharmacokinetic demonstration of selective accumulation and persistence of CF237 in human tumors relative to normal human cells and normal mouse tissues Figures 7 and 8 respectively show the pharmacokinetic profile of CF237 in human tumor xenografts relative to liver/intestine and serum of the host animals Figure 9 shows the in vitro cellular drug uptake kinetics of CF237 in a human breast tumor cell line and in normal human epithelial and endothelial cells.
The preparation of CF237 is described in commonly owned application PCT/US03/0483, as is the preparation of many other ansamycins, including many geldanamycin derivatives that can be used in connection with various aspects and embodiments of the present invention.
Tumor tissue was a human tumor cell line, MDA435, obtained from the American Type Culture Collection (ATCC), Rockville, MD, IJSA. MDA-MB-435 is a human breast tumor line isolated in 1976 by R. Cailleau, et al. from the pleural effusion of a 31 year old female with metastatic, ductal adenocarcinoma of the breast.
Cailleau R , et al. Long-term human breast carcinoma cell lines of metastatic origin:
preliminary c~aaracterization, In Vitro 14: 911-915, 1978; PubMed: 730202.
Normal human tissues were purchased from Clonetics, the BT474 tumor cells from ATCC.
Briefly, drug was administered in a single dose of 30mg/kg body weight via the intraperitoneal route in a formulation comprising 6 parts PEG400, 1 part ethanol and 3 parts Tween 80 ("PET formulation"). Test animals (3/group) were sacrificed at the indicated times after dosing (as indicated in Figures 7 and 8). Tumors were excised, minced into lmrn3 fragments and frozen at -80°C in cryovials until ready for use, at which time they were thawed and homogenized in acetonitrile, and the solvent then evaporated off under nitrogen. Extractions were then performed on the homogenate using ethyl acetatelwater. Blood samples were taken at the times indicated in Figure 8 by serial bleed from the retro-orbital sinus or the tail vein. Blood was collected into tubes, allowed to clot at room temperature for one hour and serum was collected as the supernatant after centrifugation at 300 X g for 5 minutes. The usual volume of serum available for analysis from the pharmacokinetics studies is 15~.L, although smaller volumes can be used. 485p.L acetonitrile and 15~.L
serum sample (from each time point) are added to a l.SmL siliconized microcentrifuge tube and the mixture vortexed briefly at high speed. The tubes are then centrifuged at 21,OOOxg for 10 minutes, after which the organic layer is transferred to a glass test tube. The tubes containing the organic phase are then placed in a Turbovap set at 40°C for 5-10 min. and the acetonitrile blown off using 25PSI nitrogen.
Once the tubes are totally dry, the sample is reconstituted with 150p.L of Mobile Phase (30%
Mobile Phase B Acetonitrile w! 1%Acetic Acid and 0.5% TEA/70% Mobile Phase A
H20 w/ 1% Acetic Acid and 0.5% TEA for ansamycins , 5% Mobile Phase B
Acetonitrile with 0.05% TFA/95% Mobile Phase B H20 with 0.1% TFA). The tubes ar well mixed and the contents then transferred to HPLC vials or 96-well microplates with a micro-insert. HPLC is then performed on the samples at ~160Bar using an Agilent 1100 series device with a Zorbax 300SB-CI$ column (5uM particle size;
150 x 4.6mm), UV photodiode array detector, and the following phases of solvent (30%
Mobile Phase B Acetanitrile w/ 1 %Acetic Acid and 0.5% TEA/70% Mobile Phase A
H20 w/ 1 % Acetic Acid and 0.5% TEA for ansamycins, 5% Mobile Phase B
Acetoniixile with 0.05% TFA/95% Mobile Phase B H20 with 0.1% TFA). The analysis takes approximately 15-25 minutes per sample, based on method. As controls, spiked serum standards using pooled Balb/C or Nu/Nu mouse serum containing 10, 25, 50, 500 and 5000 ng/mL of the compounds of interest were run for each analytical run per the following table.
Standard ConcentrationMouse Serum1 mg/mL Dilution (n$~~') (~,I,) Standard Scheme (Compound dissolved in Mobile Phase) 5000 497.5 2.5 NA
500 1001tL Mouse Serum +
l O 1tL 5000 ng/mL
Standard 50 200 ~L Mouse Serum +
201tL 500 nglmL
Standard 25 SO ~I Mouse Serum +
SO ltl 50 nglmL Standard 100 pl Mouse Serum 20 ttl 50 ng/mL Standard Resulting data is expressed as ng/ml or nM for serum pharmacokinetics (PK) and as ng drug/g tissue for tumor PK.
Figure 9. 18 x T75 of BT474 (Breast carcinoma) cells were compared to 9 x 5 T75 of RPTEC and HUVEC (normal cells). CF237 was added to flasks of these cells (80-90°!o confluent) at indicated times to a final concentration of luM
in 20m1 volumes. Incubations were at 37°C. Cells were harvested using Sml trypsin/flask at the times indicated in Figure 9 (i.e. 0.5, 2, 4, 8, 16 and 24 hours) neutralized with Sml medium, spun down, resuspended in 1mI PBS buffer, spun down again in an 10 Eppendorf centrifuge for lmin @ 13000 rpm, the supernatant aspirated and the product stored at -20°C for later analysis. Analysis was made by suspending the pellets in 1 mL of lysing buffer on ice for 30 min, after which centrifugation was performed @ 14000 Rl'M for 15 min @ 4°C, and the product suspended in 3 mL of ethylacetate. Extracts were evaporated @ 20 psi f~r 15 min @a 30°C, reconstituted in MPA (25 mM Tris-HCl pH 7.0 40% ACN) and assayed by HPLC as described above. The results are displayed in the following table and in Figure 9:
Time Hour BT 474- RPTEC HUVEC BT BT SD
mean 474-O1 474-02 0.5 8570 203 2603 8838 8302 379.07 2 26500 894 7470 26759 26242 365.37 4 41647 _ 905 9100 42530 40764 1248.61 8 61970 1520 15483 57883 66056 5779.42 16 _1_01_90_21450 16706 77287 126517 34810.46 24 f 97677 1485 11026 94726 100628 4173.41 Example 7: Prophetic Examples of methods fox preparing radionuclide-functionalized or cytotoxin-functionalized geldanamycin derivatives Methods for synthesizing nuclides and intermediates are described in Boehm et al., J. Org. Chem., 1986, 51, 5447-5450; Eng et al., Bull. Chim. Soc.
Belges, 1986, 95, 895-914; Prestwich et al., Tetrahedron 1984, 40, 529-537; Hanson et al., Int. J.
Appli. Radiat. Isot., 1984, 35, 810-812; Corey et al., J. Am. Chem. Soc., 1974, 96, 5581-5583; and Bottaro et al., J. Org. Chern., 1967, 174, 424-427, Synthesis and Applications of Isotopically Labelled Compounds, Volume 7 Ulrich Pleiss (Editor), Rolf Voges (Editor), ISBN: 0-471-49501-8, January 2001; Jalilian et al. J
Pharm Pharmaceut Sci. 2000, 3, 114-124. Two additional citations for preparing radioactive iodine compounds include John et al., An improved synthesis -of [125I]N-(diethylaminoethyl)-4-iodobenzarnide: a potential ligand for imaging malignant melanoma, Nuclear Medicine and Biology (1993), 20(1), 75-9. CODEN: NMBIEO
ISSN:0883-2897. CAN 118:212605 AN 1993:212605 CAPLUS, and Chumpradit, S.; Kung, M. P.; Billings, J.; Mach, R.; Kung, H. F. Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPELT. Journal of Medicinal Chemistry (1993), 36(2), 221-8. CODEN: JMCMAR ISSN:0022-2623. CAN
118:254670 AN 1993:254670 CAPLUS. Based on the foregoing, the following prophetic synthetic schemes and products are hypothesized to be produced and have useful effect according to various aspects and embodiments of the invention.
Scheme I
O OH
I I O H2N ~ I 0 'H I _Na2S204 HO ~2NOC0 I EtOAc HQ OHZ OCO
I
i0 _ i0 i0 _ i0 Bu3Sn ~ I H OH Bu3Sn ~ H ' O
Bu Sn ~ N
3 w I CI O W I O W N I I O
O
---° Y H I A~~ H I
THF, MS 4A H~ ~z OCO I MeON, SiOz HO ~2NOC0_ \ : I
i0 _ i0 i0 _ i0 N
NatzSi, i-izOz O N
H I
CN3COzH,~ HO ~2NOCQ
buffer, 12 h I
i0 ' ,O
Scheme II
H v ~cHz)~ Nhi2 ~cH2)~~N
Bu3Sn~
Bu3Sn' v 'N
H
TNF
- ~ 0 Na~2s~ ~z5~
-----Scheme III
NH ~ZSI
~(CH2)L
125~~
THF
,v Scheme IV
O
Ba(OH)2 THFlH20, 65°C
VIVIC
VIVIe Tf2O ~g(OH)2 (i-Pr NEt CH CI p H
)a ~ a 2 Pd2dba3, CsBr off HzNOCO I
CsF, dioxane Me0 vme _ OMe Scheme V
H ~ H O
HzN~N I I O HN~N O
H I ~~CHa~ I~CHa I I N
ii O H l HO_ ~ZNOCO HO HZNOCO
I NaH, THF
i0 _ i0 r0 _ s0 Scheme VI
N N O ttCHs~ ~~CH3 H O
I I O -----~. /~N~N O
NaH, THF I I
'H I H I
HO ~zNOCO I HO ~~NOCO I
s0 _ i0 i0 _ i0 Scheme VII
H H O
NON (Kl2.2.2JtaF- H H O
I I o ~ NON I I p NaN, THF
o H I H I
HO HZNOCO O
I HO HZNOCO_ I
O ' \ -TosO ~O ~O
yaF i0 ([K/2.2.2J ~ BF - is an aminopolyether potassium complex [Kryotofix 2.2.2] ~
Scheme VIII
H v ,~, taF~
R~sN
Kl2.2.2Jt aF-HO HZNOCO
NaN, TNF
i0 _. i0 /v R = -OTs or CF3S03-Scheme IX
H a HZN~N I I O ~aF~N~
IaF~OTs H
Na OEt, DMF
_ ~ ~O
Scheme X
(CHa)zN a H O CF3SOa -(CHa)aN+
W I N O ~/ I H O
O I I II N O
CHzCIz, CF~S03CH3 O I I
HO H NOCO I ~ p H
HO HZNOCO
,O
i0 - ,O
'BF
H O
I N O
Kryptofixzzz. DMSO, O I I N
SepPak ~ p H
,O
Scheme XI
H v H v I W N I I O I ~ N I I O
(CHa)zN / O H I CFaSOa -(CHa)aN+ i O
HO HzNOCO I CN2CIz, HO H2NOC l0 O _ O CF3S~ O ~
i i s - i0 H v N
I I I O
Krypfofixzza DMSO, ~BF
SepPak O H
HO HzNOCO
,O _ ,O
Scheme XII
CF3SO3 (CH3)3N+
~aF
\ O
O H H O \ I
O N ~ N ~ N Kryptofix222, DMSO O H O H O
O
I H I 1 I I N SepPak ° I I N~N~N I I\ °
OCONH~ OH O H I I \H II H I
I , / HO HpNOCO I I OCONH~ OH HO ~aNOCO
\ I
Ow _ Ow i0 _ i0 _ / \
O~ _ O~ i0 _ i0 Scheme XIII
iCHs)zN
/~N~O H O
O ~ _N J1 CHzCIz, CF3SO3CH3 ---HO HZNOCO I HO OHzNOCO
0 - i0 \ _ ~O
Kryptofixzz2, DMSO, SepPak i' s~
Scheme XIV
~zsl / \
H O
~N O
O
Naizsi yz02 AcOH
> p pN 9 buffer HO H2NOC0 _ I o i Scheme XV
HzN ~ n HzN
O H ~ 2 z a r H
HO H NOCO > OH
z ~ EtOAc HO HzNOCO
i0 _ i0 i0 _ i0 CI C~N CI
H OH CI ~CI
N a ~N o H O
O
CI \ I CI O \ ~ W I N
O
~H I Air ox. O N
HO OHNOCO
TNF, MS 4A z I MeOH, SiOz O H
HO HZNOCO
,O - ,O
i0 - ,Q
Scheme XVI
cl ie0 CIA / H O
I I O THF \ ~ I~ N
N ----~ I I p H I ~'~
HO pHZNOCO I H2N ~ ~ N.~CI O H l HO HzNOCO
,O _ ~p CI
,O _ i Scheme XVII
H a I I O TNF CI~N~N
O H I I I N O
HO HZNOCO I HZN~N-SCI CI O H
HO HZNOCO
CI
3 _ i0 ,O - ,O
* * *
The foregoing examples are not limiting and are merely illustrative of various aspects and embodiments of the present invention. All documents cited are indicative of the levels of skill in the art to which the invention pertains. The reagents used, other than those novel reagents of the invention, are commercially available and/or readily synthesized or acquired by one of ordinary skill in the art without undue effort. The disclosure of each document is incorporated by reference herein to the same extent as if each had been incorporated by reference in its entirety individually, although none of the documents is admitted to be prior art.
One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described illustrate preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Certain modifications and other uses will occur to those skilled in the art, and are encompassed within the spirit of the invention, as defined by the scope of the claims.
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the invention and the following claims.
The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, while the terms "comprising", "consisting essentially of ' and "consisting of," each carries a different meaning as a transition phrase, each such phrase may be used in lieu of the others to demonstrate a different aspect or embodiment of the invention. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described, or portions thereof. It is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modifications and variations of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.
In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group, and exclusions of individual members as appropriate.
Other embodiments are within the following claims.
We claim:
A fundamental step in identifying and evaluating HSP90 ligands is to be able to conveniently assay their binding affinity for HSP90. A variety of nonisotopic procedures, e.g., colorimetric, enzymatic, and densitometric, afford sufficient sensitivity in other contexts where they are preferred over isotopic procedures for health and disposal reasons, and Chiosis et al., Chemistry and Biology, 8:289-(2001), recently described a procedure for evaluating HSP90 ligand ability.
The Chiosis procedure, however, is cumbersome and time-consuming from the standpoint of requiring gels to be run, blotted, and probed with antibody. The Chiosis assay is further limited in its ability to conveniently support high-throughput screening.
Further, it appears that Chiosis employed a standard form of HSP90 that is characteristic of normal, healthy cells.
Needed are new diagnostic agents and therapies based on selective targeting of the HSP90 conformation that typifies cancerous, tumorous and infected cells.
SUMMARY OF THE INVENTION
The aspects and embodiments of the present invention build on those featured in PCT/US02/39993, which reported the identification of high-affinity conformations of HSP90 in cancer cells and uses thereof in HSP90 binding assays and HSP90 inhibitor identification. This application features the use of such high-affinity agents in vitro and/or in vivo to selectively target cells containing such high affinity forms for, on the one hand, diagnostic and prognostic assessment, and on the other hand for selective therapeutics and/or prophylactic protection against diseases and afflictions mediated and/or characterized by high affinity forms of HSP90. Applicants' report herein of the selective accumulation and persistence of HSP90 inhibitors in tumor and cancer cells relative to normal cells suggests that these agents will find excellent use as both diagnostic and therapeutic agents.
Thus, in a first aspect the invention features a diagnostic or cytotoxic composition having an HSP90 inhibitor functionalized with an additional moiety that affords imaging and/or cytotoxin properties. The HSP90 ligand preferably includes a member selected from the group consisting of purines, ansamycins, radicicol, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles. In some preferred embodiments, the inhibitor is a benzoquinoid ansamycin, preferably derivatized at position 17 with the cytotoxic and/or imaging agent/moiety. One embodiment for such a compound may be generically illustrated by the following formula, wherein X comprises the functional moiety, and wherein positions 4 and 5 are optionally both hydroxylated.
In some preferred embodiments, the functional moiety comprises a radioisotope/radionuclide, e.g., one selected from the group consisting of Iodenetzs, Iodenet3l, Technitium99m , Indiumltt, Rheniumt88, Gallium6~, Copper6~, Yttrium9o, and Astatine2l, ~aF, t tC, t3N, iz3h tz4h izsh t3lh zi3Bi and 150.; it is expected that these will find use not only as cytotoxic agents but also as imaging agents.
In other 1 S preferred embodiments, the functional moiety comprises a muslin or mustard-type molecule. Illustrative species of these two embodiments include compounds of formulas p I
0 ~
HN
HN ~ , ~zs ~HN I % ~ s NCI N
1 ~I~a 33~
Radionuclide moieties I I
Radjonuclide treatment ~
H HN
p ' N~N~CI ~ ~ ~ NCI
HN
/ ~~i F~a CI I
Radionuclide scanning (Positron Emission Tomography or PET) nitrogen mustard or "muslin"
Common isotopes are: 18F, 11C, 13N, 1231, 124) and 150 moieties In addition or as an alternative to the foregoing, the functional moieties of the invention may also include a member selected from the group consisting of antibodies, recombinant products, small molecules, antineoplastic agents, herceptin, taxol, taxanes and taxane derivatives, gleevec, alkylating agents, anti-rnetabilites;
epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor;
procarbazine;
mitoxantrone; platinum coordination complexes; biological response modifiers/growth inhibitors; hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors, anthracycline drugs, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, tepothilones, discodermolide, pteridine drugs, diynenes, podophyllotoxins, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin, podo-phyllotoxin derivatives, etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel, estramustine, carboplatin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT -11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.
In another aspect, the invention features a method of treating or preventing an HSP90-mediated disease by administering to a subject a pharmaceutically effective amount of a composition according to the preceding aspect and embodiments. The disease can be a neoplastic disease or one established of fostered by a pathogen, e.g., a virus, bacteria, or fungus. In some preferred embodiments, the disease is a cancer or tumor, preferably one selected from the group consisting of melanoma, breast, lung, or prostate cancer or tumor. In some embodiments, the diseased cells express supra-normal levels of Her-2 transcript, protein, or HSP90 client proteins. The treatment may be administered, e.g., orally, topically, subcutaneously, intramuscularly, intratumorally, parenterally or intravenously.
In some embodiments, the administration is made to removed tissues or cells of an organism (ex vivo). In other embodiments, the administration is made to the living organism itself (in vivo), which may entail an in situ administration directly to the site of a tumor and/or a general systemic administration. Preferably the subject is a mammal, more preferably a human. In some embodiments, the treatment is part of a chemotherapy regimen.
In another aspect, the invention features a method of diagnosing or monitoring the progression or regression of an HSP90-mediated disease by administering to the cells of a subject having or suspected of having an HSP90-mediated disease a composition according to the first aspect, and then evaluating those cells for the presence of underlying compound. Because the compound selectively accumulates and persists in diseased cells, it is easy to image such cells using, e.g., the well-known procedure of positron emission tornography (PET) or equivalent imaging technology.
The images created can, e.g., assist surgeons in identifying more precisely the location of turnorous or cancerous cells so as to excise or biopsy them. Alternatively, the imaging can be used to help diagnose disease or monitor its progression, regression, or the effect of treatment thereon. In the case of infectious diseases, normal cells and infected cells or tissues can be compared for the relative presence and/or concentration of the compounds of the invention as a measure of the disease state, or as a measure of therapy progress.
Additional advantages, aspects, and embodiments of the invention will be apparent from the figures, the detailed description, and claims to follow.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows competitive binding of geldanamycin and biotinylated geldanamycin for HSP90.
Figure 2 shows competitive binding of 17-allyl amino geldanamycin (17-AAG) and biotinylated geldanamycin for HSP90.
Figure 3 shows competitive binding of free geldanamycin, 17-AAG, and biotinylated geldanamycin for HSP90 .
Figure 4 shows that 17-AAG (CF7) has a higher apparent binding affinity for HSP90 from tumor cells (BT474) than normal cells (fibroblasts, RPTEC) or purified HSP90 alone, as determined using methods described herein.
Figure 5 shows that 17-AAG (CF7) has a higher apparent binding affinity fox HSP90 from the specific high Her2 expressing cells, SKOY-3, SKBR-3, and N87, than from normal cells, heat-shocked HSP90, or bis-ANS treated HSP90.
Figure 6 shows the results of various test compounds used in certain assay embodiments of the invention. The cell line used was MCF7. Synthesis and use of the modulators shown is described in PCT/US02129715.
Figure 7 shows the pharmacokinetic proftle of CF237 in a subcutaneous human tumor xenograft and in the liver and intestine of the host mice.
Figure 8 shows the pharmacokinetic proftle of CF237 in a subcutaneous human tumor xenograft and in the blood of the host mice.
Figure 9 shows the in vitro cellular drug uptake kinetics of CF237 in a human tumor breast tumor cell line and in normal human epithelial and endothelial cells.
DETAILED DESCRIPTION OF THE INVENTION
Definitions Compounds of the invention may embrace pharmaceutical salts of the underlying compounds. When a compound is named or displayed, it will be understood that pharmaceutically acceptable salts of such compound are also subsumed within the deftnition or structure.
A "pharmaceutically acceptable salt" may be prepared for any compound of the appropriate aspect of the invention having a functionality capable of forming a salt, for example an acid or base functionality. Pharmaceutically acceptable salts may be derived from organic or inorganic acids and bases. Compounds of the invention that contain one or more basic functional groups, e.g., amino or alkylamino, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable organic and inorganic acids. These salts can be prepared in situ during the Enal isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, malefic, phosphoric, glycolic, gluconic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic, 1,2 ethanesulfonic acid (edisylate), galactosyl-d-gluconic acid, and the like. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, may be employed in the preparation of pharmaceutically acceptable acid addition salts. See, e.g., Berge et al. "Pharmaceutical Salts", J. Pharm. Sci.
66:1-19 (1977).
Compounds of the present invention that contain one or more acidic functional groups are capable of forming pharmaceutically-acceptable salts with pharmaceutically- acceptable bases. The term "pharmaceutically-acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the.
hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically- acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
Illustrative examples of some of the bases that can be used include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, and the like. Representative organic amines useful for the formation of base addition salts include ethyl amine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. See, for example, Berge et al., supra.
A "pharmacological composition" refers to a mixture of one or more of the compounds described herein or pharmaceutically acceptable salts thereof, with other chemical components, such as pharmaceutically acceptable carriers and/or excipients.
The purpose of a pharmacological composition is to facilitate administration of a compound to an oxganism.
The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol arid polyethylene glycol; (12) esters, such as ethyl oleate and ethyllaurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water;
(17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. A physiologically acceptable carrier should not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
An "excipient" refers to an inert substance added to a pharmacological composition to further facilitate administration of a compound. Examples of excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
A "pharmaceutically effective amount" means an amount which is capable of providing a therapeutic and/or prophylactic effect. The specific dose of compound administered according to this invention to obtain therapeutic and/or prophylactic effect will, of course, be determined by the particular circumstances surrounding the case, including, for example, the specific compound administered, the route of administration, the condition being treated, and the individual being treated.
A typical daily dose (administered in single or divided doses) will contain a dosage level of from about 0.01 mg/kg to about 50-100 mg/kg of body weight of an active compound of the invention. Preferred daily doses generally will be from about 0.05 mg/kg to about 20 rng/kg and ideally from about 0.1 rnglkg to about 10 mg/kg. Factors such as clearance rate and half life and maximum tolerated dose (MTD) have yet to be determined but one of ordinary skill in the art can determine these using standard procedures.
In some method embodiments, the preferred therapeutic effect is the inhibition, to some extent, of the growth of cells characteristic of a proliferative disorder, e.g., breast cancer. A therapeutic effect will also normally, but need not, relieve to some extent one or more of the symptoms other than cell growth or size of cell mass. A therapeutic effect may include, for example, one or more of 1) a reduction in the number of cells; 2) a reduction in cell size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cell infiltration into peripheral organs, e.g., in the instance of cancer metastasis; 3) inhibition (i.e., slowing to some extent, preferably stopping) of tumor metastasis; 4) inhibition, to some extent, of cell growth;
and/or 5) relieving to some extent one or more of the symptoms associated with the disorder.
In some preferred embodiments of the invention, the "IC50" value of a compound of the invention is greater for normal cells than for cells exhibiting a proliferative disorder, e.g., breast cancer cells. The value depends on the assay used.
By a "standard" is meant a positive or negative control. A negative control in the context ofHER-2 expression levels is, e.g., a sample possessing an amount ofHER-2 protein that correlates with a normal cell. A negative control may also include a sample that contains no HER-2 protein. By contrast, a positive control does contain HER-2 protein, preferably of an amount that correlates with over-expression as found in proliferative disorders, e.g., breast cancers.. The controls may be from cell or tissue samples, or else contain purified ligand (or absent ligand), immobilized or otherwise. In some embodiments, one or more of the controls may be in the form of a diagnostic "dipstick."
By "selectively targeting" is meant affecting one type of cell to a greater extent than another, e.g., in the case of cells with high as opposed to relatively low or normal Her-2 levels.
HSP90 Li~ands HSP90 Iigands useful in the compositions and methods of the invention include, e.g., purines, ansamycins, radicicol, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles, which compounds are well-known in the art.
Preferred are ansamycins, which are known to inhibit HSP90 function. The term "ansamycin" as used herein is well-known in the art and refers to a broad class of structures characterized by aliphatic rings of various length and constitution bridging opposite ends of aromatic ring structures and their reduced equivalents.
Subsumed within this broad class is the sub-class, benzoquinone ansamycins. A
"benzoquinone ansamycinin" as used herein possesses a benzoquinone as the aromatic ring structure and includes any benzoquinone ansamycin known in the art having an alkoxy moiety on the benzoquinone portion of the molecule, preferably a methoxy, and preferably at the 17 position, that can be replaced by a nucleophile. The result of the reaction is the formation of a "benzoquinone ansamycin derivative." Ansarnycins further include dimers and pharmaceutically acceptable salts of the ansamyin compound.
Ansamycins may be synthetic, naturally-occurring, or a combination of the two, i.e., "semi-synthetic." Exemplary ansamycins useful in the processes of the invention and their methods of preparation include but are not limited to those described, e.g., in U.S. Patents 3,595,955 (describing the preparation of geldanamycin), 4,261,989, 5,387,584, and 5,932,566. Geldanamycin is also commercially available, e.g., from CN Biosciences, an affiliate of Merck headquartered in San Diego, California, USA
(cat. no. 345805). The biochemical purification of 4,5-Dihydrogeldanamycin and its hydroquinone from cultures of Streptomyces hygroscopicus (ATCC 55256) are described Cullen et al. in International Application Number PCT/US92/10189 (WO
93/14215), assigned to Pfizer Inc. An alternative method of synthesis for 4,5-Dihydrogeldanamycin by catalytic hydrogenation of geldanamycin is also known.
See, e.g., Progress in the Chemistry of Organic Natural Products, Chemistry a/the Ansamycin Antibiotics, 33 1976, p. 278. Applicants recently described the preparation of numerous other ansamycin compounds in commonly owned co-pending applications PCT/LJS03/04283 and PCT/LJS02/29715, including the dimer CF237 which appears in one of the examples below.
HSP90s HSP90 proteins are ubiquitous cellular proteins that are highly conserved in nature. The term "an HSP90" or "an HSP90 member" as claimed herein includes but is not limited to the following: NCBI accession #'s P07900 and XM 004515 (human a and ~3 HSP90 respectively), P11499 (mouse), AAB2369 (rat), P46633 (chinese hamster), JC1468 (chicken), AAF69019 (flesh fly), AAC21566 (zebrafish), AAD30275 (salmon), 002075 (pig), NP 015084 (yeast), and CAC29071 (frog).
Further included in the definition are any variations of such proteins that may exist in nature or that are man- made. All are expected to have more or less utility in connection with the methods, assays, and ligands of the invention, e.g., in identifying and/or quantifying binding affinities of various HSP90 ligands, and thereby identifying andlor prioritizing new drug candidates for clinical trials. One aspect of the invention exploits Applicants' finding that cancer and tumor cells possess a more sensitive, high affinity, form of HSP90s than do normal cells. Ligands bind HSP90s found in cancer or tumor cells much more avidly despite the protein itself having an identical amino acid constituency. Without being limiting of the invention, this is thought to be a consequence of a different tertiary or quarternary configuration of the protein that is present in such cells, possibly being afforded by co-chaperone proteins or client proteins that are bound to the HSP90 to make it behave as such.
The following discussion sections concerning labeling and solid supports and high throughput screening are borrowed largely from United States Patents 6,203,989, 6,153,442, 6,096,508, 5,846,537, and 5,585,241. The procedures described therein and below can be assimilated, adapted, and/or otherwise implemented in furtherance of the novel and unobvious features of the present invention.
Labels and Labeling The following discussion sections concerning labeling and solid supports and high throughput screening are borrowed largely from United States Patents 6,203,989, 6,153,442, 6,096,508, 5,846,537, and 5,585,241. The procedures described therein and below can be assimilated, adapted, and/or otherwise implemented in furtherance of the novel and unobvious features of various aspects and embodiments of the present invention.
Biotin:(Strept)Avidin Labels. Some preferred embodiments of the invention exploit the natural high affinity of streptavidin for biotin. Streptavidin is related to avidin, a 67 kilodalton (kD) glycoprotein found in e~g whites and which has an exceptionally high binding affinity (Kd =l0-15 M) for biotin. Avidin consists of four subunits, each capable of binding one biotin molecule.
Streptavidin is produced by Streptomyces avidihii and shares significant conformation and amino acid composition with avidin, as well as high affinity for biotin and stability.
Streptavidin is also not glycosylated and reportedly exhibits less non-specific binding than avidin, making it the superior choice of the two for most biotin-based applications.
Biotin, a member of the B-complex vitamins, is found naturally and is essential for amino acid and fatty acid degradation, gluconeogenesis, and fatty acid synthesis. The binding interactions between biotin and the biotin binding site of avidin and streptavidin are the result of non covalent hydrogen bonding and van der Waals interactions between biotin and avidin, together with the ordering of surface polypeptide loops that bury the biotin in the protein interior. Biotin has previously been chemically or enzyrnatically coupled extensively to probe biomolecules in ways that minimize interference with target recognition, and the results described herein for geldanamycin provide further examples of how this may be done.
Reagents for labeling streptavidin or avidin with a fluorescent tag are commercially available. For example, the reagents, 5(6)-Carboxyfluorescein-N-hydroxysuccinirnide ester (FLUOS), 7-amino-4-methyl-coumarin-3-acetic acid-N'-hydroxysuccinimide ester (AMCA, activated) and fluorescein isothiocyanate (FITC) are available from Boehringer Mannheim, Indianapolis, Ind., USA. Methods for fluorescently labeling proteins with fluorescent labels, and methods for detection of the fluorescent labels, are described in Howard, G., Labeling Proteins with Fluorochromes, in "Methods in Nonradioactive Detection,", G, Howard; Ed., Appleton and Lange, Norwalk, Conn, USA. 1993, pp. 39-6~, the disclosure of which is incorporated herein. Additionally, there are a variety of commercially available streptavidin- and avidin-labeled molecules. Examples include streptavidin-gold, streptavidin-fluorochrorne, streptavidin-AMCA, streptavidin- fluorescein, streptavidin-phycoerythrin (STPE), streptavidin-sulforhodamine 101, avidin-FITC
and avidin-Texas red.RTM:, which are commercially available from Boehringer Mannheim, Indianapolis, Ind., USA. A working example of the use of streptavidin-phycoerythrin in the methods and reagents of some aspects and embodiments of the invention is described below.
In addition to the biotin-steptavidin system described above, other labels or label complexes can also be used to generate a detectable signal to relate the amount of bound and/or unbound label. The label can be any molecule that produces or can be induced to produce a signal, and may be, for example, a fluoresces, radio-label, enzyme, dense element such as gold, chemiluminescer or photosensitizes. Thus, the signal, depending on the label embodiment, can be detected and/or measured by detecting enzyme activity, luminescence, light absorbance or radioactivity as the case may be. In some applications, nonradioactive applications are preferred.
Specific labels that can be used illustratively include, e.g., enzymes such as alkaline phosphatase, glucose-6-phosphate dehydrogenase ("G6PDH") and horseradish peroxidase;.dyes; fluorescers such as fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, and fluorescamine; chemiluminescers such as isoluminol; sensitizers; coenzymes;
enzyme substrates; radiolabels such as 125 I, l31 I, l4 C, 3 H, 57 Co and 75 Se; panicles such as latex, or carbon particles; metals;
crystallite;
liposomes; cells, photoactivatable compounds etc., which may be further labeled with a dye, catalyst or other detectable group. Other suitable enzymes and coenzymes are disclosed in Litman, et al., U.S. Pat. No. 4,275,149, columns 19-28, and Boguslaski, et al., U.S. Pat. No. 4,318,980, columns 10-14. Suitable fluorescers and chemiluminescers are disclosed in Litman, et al., U.S. Pat. No. 4,275,149, at columns 30 and 31. Photoactivatable compounds include but are not limited to those containing reactive enediyne and terminal diazo groups, e.g., the natural products Dynemicin, Kinamycin C, and Prekinamycin, as disclosed at http~//www Indiana edu/~zale~rt~/overview acs.html. Others include, e.g., UVADEX
and Methoxypsoralen (8-MOP) that are reported efficacious in extracorporeal photochemotherapy (ECP), as well as TER286 [g-glutarnyl-a-amino-b(2-ethyl-N,N,N',N'-tetrakis (2-chloroethyl) phos-phorodiamidate)-sulfonyl)-propionyl-(R)-(-) phenylglycine] (a nitrogen mustard prodrug) and 35S]-azidophenacyl-glutathione ([35S]APA-SG), chlorins, porphyrins, and phthalocyanines. See, e.g., htt~:l/www.ibmtindy.com./faq/photopheresis.htm;
htty//www fccc.edu/research/reports/current/tew.repoutframe.html http ~//www.info.med.yale.eduldermatolo~/clinical/nhoto.html;
http~/lsearch msn.com/results.asp?FORM=sCPN&RS=C:HECKED&un=doc~v=1&~
~hotoactivatable°1o20dru~; Qualls et al., "Synergistic Phototoxicity of Chloroaluminum Phthalocyanine Tetrasulfonate Delivered via Acid-Labile Diplasmenylcholine-Folate Liposomes", International Journal of Cancer 2001, 93, 384-392. Each of the preceding is herein incorporated by reference.
The label used may directly produce a signal. Alternatively, the label may indirectly produce a signal and therefore require additional reagents and/or physical stimulation, e.g., bombardment with electromagnetic energy or the addition of a chemical substrate or co-factor. In the instance of fluorescers, for example, these are able to absorb ultraviolet and visible light where the light absorption transfers energy to these molecules and elevates them to an excited energy state, which absorbed energy is then dissipated by emission of light at a second wavelength. By contrast, labels that directly produce a signal include, e.g., radioactive isotopes and dyes.
Examples of labels that need other reagent components to produce a Signal include, e.g., substrates and coenzymes (for enzyme labels), substances that react with enzymic products, catalysts, activators, cofactors, inhibitors, scavengers, metal ions, and a specific binding substance required for binding of signal generating substances.
Additional discussion of suitable labeling systems can be found, e.g., in Ullrnan, et al., U.S. Pat. 5,155,243, columns 11-13, the disclosure of which is herein incorporated by reference.
The assay methods of the invention may be conveniently performed on a solid support, such as in multi-well plates for an ELISA or on any solid support for high density or chip array analysis, for example, in an ELISA type format, the ligand or receptor molecule is adsorbed to a solid support such as the wells of a 96-well plate.
The corresponding complement (receptor or ligand, whichever the case may be), is/are added to the wells and incubated. Alternatively, the complexes may first be formed and then adhered to the solid support, to be competed with later by another ligand or compound of interest. In yet another embodiment, multiple ligands, at least one of which is known and labeled, are mixed together in the presence of an and, by whichever of a broad variety of means known in the art, noncomplexed and nonadhered species (in solid support embodiments) are removed. The amount of label is then assessed using a detection device. Removal of noncomplexed and nonadhered species can be done by wash steps, and in some embodiments, centrifugation.
Unbound ligand/receptor is washed away and the presence of labeled complex is then detected. Many variations are possible.
Detection hardware devices that can be used in connection with various embodiments of the present invention are well known in the art and include but are not limited to, e.g., densitometers, mass spectrometers, fluorometers, scintillation counters, spectrophotometers, nrnr devices, positron emission tomography (PET) devices, luminometers, cameras, and other imaging or detection devices. These devices and their use are all well known in the art. For example, PET is described in Mandelkern et al., Positron enaission tonaography in cancer research and treatment.
Technologies in Cancer Research and Treatment (2002) 1(6):423-39, and Zimny et al., Positron emission tomography scanning in gynecologic and breast cancers, Current Opinion in Obstetrics and Gynecology. (2003) 15(1):69-75.
Assays to Determine HSP90 Binding and Downstream Effect .
In addition to the innovations described herein, a variety of in vitro and in vivo assays are available to test the effect of the compounds of the invention on HSP90.
HSP90 competitive binding assays and functional assays can be performed as known in the art substituting in the compounds of the invention. Chiosis et al., Chemistry &
Biology 8:289-299 (2001 ) describe some of the known ways in which this can be done. For example, competition binding assays using, e.g., geldanamycin or 17-AAG
as a competitive binding inhibitor ofHSP90 can be used to determine relative affinity of the compounds of the invention by immobilizing the compound of interest or other competitive inhibitor on a gel or solid matrix, preincubating HSP90 with the other inhibitor, passing the preincubated mix over the gel or matrix, and then measuring the amount of HSP90 that sticks or does not stick to the gel or matrix.
Downstream effects can also be evaluated based on the known effect ofHSP90 inhibition on function and stability of various steroid receptors and signaling proteins including, e.g., Rafl and Her2. Compounds of the present invention induce dose-dependent degradation of these molecules, which can be measured using standard techniques. Inhibition of HSP90 also results in up-regulation of HSP90 and related chaperone proteins that can similarly be measured. Antiproliferative activity on various cancer cell lines can also be measured, as can morphological and functional differentiation related to HSP90 inhibition.
Many different types of methods are known in the art for determining protein concentrations and measuring or predicting the level of proteins within cells and in fluid samples. Indirect techniques include nucleic acid hybridization and amplification using, e.g., polymerase chain reaction (PCR). These techniques are known to the person of skill and are discussed, e.g., in Sarnbrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, NY, 1994, and, as specifically applied to the quantification, detection, and relative activity of Her-2/neu in patient samples, e.g., in U.S. Patents 4,699,877, 4,918,162, 4,968,603; and 5,846,749. A brief discussion of two generic techniques that can be used follows.
The determination of whether cells over-express or contain elevated levels of HER- 2 can be determined using well known antibody techniques such as immunoblotting, radioimmunoassays, western blotting, iminunoprecipitation, enzyme-linked immunosorbant assays (ELISA), and derivative techniques that make use of antibodies directed against HER-2. As an example, HER-2 expression in breast cancer cells can be determined with the use of an immunohistochernical assay, such as the Dako HercepTM test (Dako Corp., Carpinteria, CA). The HercepTM test is an antibody staining assay designed to detect HER-2 over-expression in tumor tissue specimens. This particular assay grades HER-2 expression into four levels: 0, l, 2, and 3, with level 3 representing the highest level of HER-2 expression.
Accurate quantitation can be enhanced by employing an Automated Cellular Imaging System (ACIS) as described, e.g., by Press, M, et al. , 2000, Modern Pathology, 13:225A.
Antibodies, polyclonal or monoclonal, can be purchased from a variety of commercial suppliers, or may be manufactured using well-known methods, e.g., as described in Harlow et al" Antibodies: A Laboratory Manual, 2nd Ed; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1988).
HER-2 over-expression can also be determined at the nucleic acid level since there is a reported high correlation between over-expression of the HER-2 protein and amplification of the gene that codes for it. One way to test this is by using RT - PCR.
The genomic and cDNA sequences for HER-2 are known. Specific DNA primers can be generated using standard, well-known techniques, and can then be used to amplify template already present in the cell. An example of this is described in Kurokawa, H.
et al., Cancer Res. 60: 5887-5894 (2000). PCR can be standardized such that quantitative differences are observed as between normal and abnormal cells, e.g., cancerous and noncancerous cells. Well known methods employing, e.g., densitometry, can be used to quantitate and/or compare nucleic acid levels amplified using PCR.
Similarly, fluorescent in situ hybridization (FISH) assays and other assays can be used, e.g., Northern and/or Southern blotting. These rely on nucleic acid hybridization between the HER-2 gene or mRNA and a corresponding nucleic acid probe that can be designed in the same or a similar way as for PCR primers, above.
See, e.g., Mitchell, MS, and Press, MF, 1999, Semin. Oncol., Suppl. 12:108-16.
For FISH, this nucleic acid probe can be conjugated to a fluorescent molecule, e.g., fluorescein andlor rhodamine, that preferably does not interfere with hybridization, and which fluorescence can later be measured following hybridization. See, e.g., Kurokawa, H et al., Cancer Res. 60: 5887- 5894 (2000) (describing a specific nucleic acid probe having sequence 5'-FAM- NucleicAcid-TAMRA-p-3' sequence). ACIS-based approaches as described above can be employed to make the assay more quantitative (de la Torre-Bueno, J, et al , 2000, Modem Pathology 13:221A).
Immuno and nucleic acid detection can also be directed against proteins other than HSP90 and Her-2, which proteins are nevertheless affected in response to inhibition.
Pharmaceutical Compositions, Dosa~in~ and Modes of Administration Compounds identified as promising using the assays of the invention can in turn be formulated into pharmaceutical compositions and then administered to subj ects.
Those of ordinary skill in the art are familiar with formulation and administration techniques that can be employed with the compounds and methods of the invention, e.g., as discussed in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition; Pergamon Press; and Remington Pharmaceutical Sciences (current edition.), Mack Publishing Co., Easton, Pa., USA.
The compounds utilized in the methods of the instant invention may be administered either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharniaceutical practice. The compounds can be administered orally or parenterally, are nevertheless affected in response to HSP90 including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
For example, the therapeutic or pharmaceutical compositions of the invention can be administered locally to the area in need of treatment. This may be achieved by, for example, but not limited to, local infusion during surgery, topical application, e.g., cream, ointment, injection, catheter, or implant, said implant made, e.g., out of a porous, non- porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. The administration can also be by direct injection at the site (or former site) of a tumor or neoplastic or pre-neoplastic tissue.
Still further, the compounds or compositions of the invention can be delivered in a vesicle, e.g., a liposome (see, for example, Langer, 1990, Science, 249:1527-1533; Treat et al., 1989, Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Bernstein and Fidler (Eds.), Liss, N.Y., USA, pp. 353-365).
The compounds and pharmaceutical compositions used in the methods of the present invention can also be delivered in a controlled release system. In one embodiment, a pump may be used (see, Sefton, 1987, CRC Grit. Ref. Biomed. Eng.
14:201; Buchwald et al., 1980, Surgery, 88:507; Saudek et al., 1989, N. Eng.
J. Med., 321:574). Additionally, a controlled release system can be placed in proximity of the therapeutic target (see, e.g., Goodson, 1984, Medical Applications of Controlled Release, Vol. 2, pp. 115-138).
The pharmaceutical compositions used in the methods of the instant invention can also contain the active ingredient in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according-to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as microcrystalline cellulose;
sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be un-coated or coated by known techniques to mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a water soluble taste masking material such as hydroxypropylrnethyl-cellulose or hydroxypropylcellulose, or a time delay material such as ethyl cellulose, or cellulose acetate butyrate may be employed as appropriate.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl cellulose, methylcellulose, hydroxypropylrnethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol aziliydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti=oxidant such as ascorbic acid.
The compounds and pharmaceutical compositions used in the methods of the instant invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be natural ly-occurnng phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening agents, flavoring agents, preservatives and antioxidants.
Syrups and elixirs may be formulated with sweetening agents, e.g., glycerol, propylene glycol: sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
The pharmaceutical compositions may be in the form of sterile injectable aqueous solutions. Acceptable vehicles and solvents that may include, e.g., water, Ringer's solution and isotonic sodium chloride solution.
The sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For example, the active ingredient may be first dissolved in a mixture of soybean oil and lecithin. The oil solution is then introduced into a water and glycerol mixture and processed to form a micro emulsion.
The injectable solutions or micro emulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous to administer the solution or micro emulsion in such a way as to maintain a constant circulating concentration of the instant compound. In order to maintain such a constant concentration, a continuous intravenous delivery device may be utilized. An example of such a device is the Deltec CADD-PLUSTM model 5400 intravenous pump.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration.
This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3- butane dial. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The Compounds of the present invention used in the methods of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the inhibitors with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing a compound or composition of the invention can be used. As used herein, topical application can include, e.g., mouth washes and gargles.
The compounds used in the methods of the present invention can be administered in intianasal form via topical use of suitable intranasal vehicles and delivery devices, or via trans dermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
The methods, compounds and compositions of the instant invention may also be used in conjunction with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated. For example, the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents. Further, the instant methods and compounds may also be useful in combination with other inhibitors of parts of the signaling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation.
The methods of the present invention may also be useful with other agents that inhibit angiogenesis and thereby inhibit the growth and invasiveness of tumor cells, including, but not limited to VEGF receptor inhibitors, including ribozymes and antisense targeted to VEGF receptors. angiostatin and endostatin.
Examples of antineoplastic agents that can be used in combination with the compounds and methods of the present invention include, in general, and as appropriate, alkylating agents, anti-metabolites; epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes; biological response modifiers and growth inhibitors;
hormonallanti-hormonal therapeutic agents and haematopoietic growth factors.
Exemplary classes of antineoplastics include theanthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the epothilones, discodermolide, the pteridine family of drugs, diynenes and the podophyllotoxins. Particularly useful members of those classes include, for example, carminomycin,. daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podo-phyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel and the like. Other useful antineoplastic agents include estramustine, carboplatin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-II, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.
When a compound or composition of the invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for cancer, for example, breast cancer.
Administration typically occurs in an amount of between about 0.01 mg/kg of body weight to about 100 mg/kg of body weight per day (administered in single or divided doses), more preferably at least about 0.1 mg/kg of body weight per day. A
particular therapeutic dosage can include, e.g., from about 0.01 mg to about 1000 mg of compound, and preferably includes, e.g., from about 1 mg to about 1000 mg. The quantity of active compound in a unit of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, preferably from about 1 mg to 300 mg, more preferably mg to 200 mg, according to the particular application. The amount administered will vary depending on the particular IC50 value of the compound used and the judgment of the attending clinician taking into consideration factors such as health, weight, and age. In combinational applications in which the compound is not the sole active ingredient, it may be possible to administer lesser amounts of compound and still have therapeutic or prophylactic effect.
Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art.
Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small amounts until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
The amount and frequency of administration of the compounds and compositions of the present invention used in the methods of the present invention, and if applicable other chemotherapeutic agents and/or radiation therapy, will be regulated according to the judgment of the attending clinician (physician) considering such factors as age, condition and size of the patient as well as severity of the disease being treated.
The chemotherapeutic agent and/or radiation therapy can be administered according to therapeutic protocols well known in the art. It will be apparent to those skilled in the art that the administration of the chemotherapeutic agent andlor radiation therapy can be varied depending on the disease being treated and the known effects of the chemotherapeutic agent andlor radiation therapy on that disease. Also, in accordance with the knowledge of the skilled clinician, the therapeutic protocols (e.g., dosage amounts and times of administration) can be varied in view of the observed effects of the administered therapeutic agents (i.e., antineoplastic agent or radiation) on the patient, and in view of the observed responses of the disease to the administered therapeutic agents.
Also, in general, the compounds of the invention need not be administered in the same pharmaceutical composition as a chemotherapeutic agent, and may, because of different physical and chemical characteristics, be administered by a different route. For example, the compounds/compositions may be administered orally to generate and maintain good blood levels thereof, while the chemotherapeutic agent may be administered intravenously. The determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the skilled clinician. The initial administration can be made according to established protocols known in the art, and then, based upon the observed.
The particular choice of compound (and where appropriate, chemotherapeutic agent and/or radiation) will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol.
The compounds/compositions of the invention (and where appropriate chemotherapeutic agent andlor radiation) may be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the proliferative disease, the condition of the patient, and the actual choice of chemothexapeutic agent and/or radiation to be administered in conjunction (i.e., within a single treatment protocol) with the compound/cornposition.
In combinational applications and uses, the compound/composition and the chemotherapeutic agent and/or radiation axe not administered simultaneously or essentially simultaneously, then the initial order of administration of the compound/composition, and the chemotherapeutic agent and/or radiation, may not be important. Thus, the compounds/compositions of the invention may be administered first followed by the administration of the chemotherapeutic agent and/or radiation; or the chernotherapeutic agent and/or radiation may be administered first followed by the administration of the compounds/compositions of the invention. This alternate administration may be repeated during a single treatment protocol. The determination of the order of administration, and the number of repetitions of administration of each therapeutic agent during a treatment protocol, is well within the knowledge of the skilled physician after evaluation of the disease being treated and the condition of the patient. For example, the chemotherapeutic agent andlor radiation may be administered first, especially if it is a cytotoxic agent, and then the treatment continued with the administration of the compounds/cornpositions of the invention followed, where determined advantageous, by the administration of the chemotherapeutic agent and/or radiation, and so on until the treatment protocol is complete.
Thus, in accordance with experience and knowledge, the practicing physician can modify each protocol for the administration of a eompound/composition for treatment according to the individual patient's needs, as the treatment proceeds.
The attending clinician, in judging whether treatment is effective at the dosage administered, will consider the general well-being of the patient as well as more definite signs such as relief of disease-related symptoms, inhibition of tumor growth, actual shrinkage of the tumor, or inhibition of metastasis. Size of the tumor can be measured by standard methods such as radiological studies, e.g., CAT or MRI
scan, and successive measurements can be used to judge whether or not growth of the tumor has been retarded or even reversed. Relief of disease-related symptoms such as pain, and improvement in overall condition can also be used to help evaluate treatment efficacy.
EXAMPLES
The following examples are offered by way of illustration only and not by way of limitation. Examples 1-3 illustrate alternative methods ofproducing a biotinylated geldanamycin, of formulalcompound 5. Example 4 illustrates that such a compound is useful in competitive binding assays with other HSP90 ligands, e.g., other ansamycins such as geldanamycin and 17-AAG. Example 5 illustrates how HSP90s taken from tumor cell lines more avidly bind known HSP90 ligands. Example 6 demonstrates the selective accumulation and persistence of CF237 (an ansamycin dimer) in mouse and human tumors. Example 7 illustrates prophetic examples of preparing radionuclide-functionalized or cytotoxin-functionalized geldanamycin derivatives.
Example 1: Synthesis of biotinylated ansamycins useful for competition binding studies with HSP90.
This example follows the scheme:
NON /v I I N
O °H ~O
S N'/~0~~O'/~'N
O ~ _ NON
O
N~ ~O~
THF S o ° NH I I °
--~ ~ ~N -~' I
RT '~~'' ° off ~o 3 o w o -wherein the compound numbers are denoted beneath the corresponding structures;
and wherein the details of the synthesis are as follows.
To 50 mg (0.134 mmol) of (+)-biotinyl-3,6-dioxaoctanediamine 1 in 3 mL of 15:1 THF-H20 was added 29.9 (0.053 mmol) of geldanamycin 2 at room temperature.
The reaction was stirred overnight, quenched with water (50 mL) and extracted with 2 x 50 mL of EtOAc. The EtOAc extracts were combined, washed with 2 x 50 mL of H20, 1 x 50 mL of brine, dried (MgS04) and purified by silica gel flash chromatography to give 88 mg (0.095 mmol) in 71 %yield of 3. MP 113-117 °C: MS
926 (M + Na).
Example 2: Synthesis of biotinylated ansamycins useful for competition binding studies with HSP90.
This example follows the scheme:
,o o I I o NON N i V
N~NH2 ~ ~ O OH 'O
S O ~ O
O I
Z H~o N~'N
H O
THF _~S~ o NON I I o ~'N ~~I
RT .~~'' o off 'o o '. o I
- NH~O
wherein the compound numbers are denoted beneath the corresponding structures, and wherein the details of the synthesis are as follows.
To 50 mg (0.152 mmol) of 5-(biotinamido)pentylamine 4 in 3 mL of 15:1 THF-H20 was added 28 mg (0.050 mmol) of geldanamycin 2 at room temperature.
The reaction was stirred overnight, quenched with water (50 mL) and extracted with 2 x 50 mL of EtOAc. The EtOAc extracts were combined, washed with 2 x 50 mL of H20, 1 x 50 mL of brine, dried (MgS04) and purified by silica gel flash chromatography to give 100 rng (0.114 mmol) of 5 in 75 % yield. MP 143-147 °C.
MS 880 (M + Na).
Example 3: Synthesis of biotinylated ansamycins useful for competition binding studies with HSP90.
This example follows the scheme:
o I I
NON N ~ I
~~~"~ O OHH ~~
-~N~..O~O~O~NHz O . ~ O
O t 6 2 = Hz o TNF
RT
wherein the compound numbers are denoted beneath the corresponding structures and the details of the synthesis are as follows.
To 50 mg (0.119 rnmol) of (+)-biotinyl-3,6,9-trioxaundecanediamine 6 in 3 mL of 15:1 THF-H20 was added 26.8 mg (0.048 mmol) of geldanamycin 2 at room temperature. The reaction was stirred overnight, quenched with water (50 mL) and extracted with 2 x 50 mL of EtOAc. The EtOAc extracts were combined, washed with 2 x 50 mL of H20, 1 x 50 mL of brine, dried (MgS04) and purified by silica gel flash chromatography to give 84 mg (0.087 mmol) of 7 in 73°!° yield.
MP 103-104 °C. MS
970 (M + Na).
Example 4: HSP90 Binding Assay Utilizing A Biotinylated Ansamycin Purified native HSP90 protein was coated onto 96-well plates by incubating for 1 hr. at 37°C. Uncoated HSP90 was removed and the wells washed twice in 1 x PBS (phosphate-buffered saline) buffer. Compound 5 (biotinylated geldanamycin) was then added to the wells, and the reaction was further incubated for lhr at 37°C.
The wells were washed twice with 1 x PBS, before the addition of 20ug/ml streptavidin-phycoerythrin, and incubated for lhr at 37°C. The wells were again washed twice with 1 x PBS. The fluorescence was then measured in a Gemini Spectrofluorometer (Molecular Devices Corp, Sunnyvale, CA, USA) using.an excitation of 485nm and emission of 580 nm.
Figures 1-3 show assay embodiments employing different HSP90 ligands.
Details of the assays are as follows:
Figure 1. Competition of biotinylated-GM (compound S) binding by free geldanamycin (GM). Native HSP90 that was coated onto 96-well plates was pre-incubated with increasing concentrations of 0 nM (B3), 100 nM(C3), 300 nM
(D3), 1000 nM (E3), 3000 nM (F3), 10,000 nM (G3), and 100,000nM (closed diamonds) of geldanamycin and then S was added. Binding of S was detected by measuring the fluorescence of streptavidin-phycoerythrin (excitation: 48S run; emission: 510-run). The background fluorescence without any HSP90 present (A3) was minimal.
Increasing concentrations of GM inhibits the peak fluorescence at 580 run.
Figure 2. Competition of biotinylated-GM (compound 5) binding by 17 -allyl amino geldanamycin (17-AAG). Native Hsp90 that was coated onto 96-well plates was pre-incubated with increasing concentrations of 0 nM (B4), 100 nM (C4), nM (D4), 1000 nM (E4), 3000 nM (F4), 10,000 nM (G4), and 100,000 nM (closed diamonds) of 17-AAG and then 5 was added. Binding of 5 was detected by measuring the fluorescence of streptavidin-phycoerythrin (excitation: 48Snm;
1 S emission: 510-650 nm). The background fluorescence without any HSP90 present (A4) was minimal. Increasing concentrations of 17-AAG inhibits-the peak fluorescence at 580 nm Figure 3. Competition ofbiotinylated-GM (compound 5) binding by geldanamyein (GM) and 17-allyl amino geldanamycin (17-AAG). Native Hsp90 that was coated onto 96-well plates was pre-intubated, with increasing concentrations of 0-100,000 nM of either GM or 17 -AAG and then S was added Binding of S was detected by measuring the fluorescence of streptavidin-phycoerythrin (excitation: 485 nm; emission: 580 nm). The background fluorescence without any HSP90 present was minimal. Increasing concentrations of GM or 17 -AAG inhibits the peak fluorescence 2S at 580 nm.
Example 5: HSP90s taken from tumor cell lines more avidly bind HSP90 ligands Purified native HSP90 protein (Stressgen) or cell lysates prepared in lysis buffer (20mM Hepes, pH 7.3, 1 mM EDTA, SmM MgCl2, lOOmM I~Cl) wexe incubated in the absence or presence of CF7 (17-AAG) or test compound for 1 Smin at 4°C. Biotin- geldanarnycin (biotin-GM) was then added to the mixture as discussed previously, and the reaction was further incubated by rotating for lhr at 4°C. ' BioMagTM streptavidin magnetic beads were then added to the mixture, and the reaction was incubated by rotating for another lhr at 4°C. Tubes were placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads were washed three times in lysis buffer, and the washes discarded. SDS-PAGE sample buffer was added to the beads and boiled for 5 min at 95°C. Samples were analyzed on 10% SDS protein gels (Novex), and then Western blots using anti-HSP90 monoclonal antibody (Stressgen SPA-830). The bands in the Western Blots were quantitated using the Bio-rad Fluor-S Imager, and the % inhibition of binding of CF7 or test compound calculated. The IC50 reported is the concentration of the compound needed to cause half maximal inhibition of binding. For experiments that utilized shocked HSP90, the purified HSP90 native protein was incubated for 15 min at 90°C.
For experiments that utilized bis-ANS treated HSP90, the purified HSP90 protein was incubated with bis-ANS (Molecular Probes) for 30 min at 37°C. The results are shown in Figures 4-6.
Example 6: Pharmacokinetic demonstration of selective accumulation and persistence of CF237 in human tumors relative to normal human cells and normal mouse tissues Figures 7 and 8 respectively show the pharmacokinetic profile of CF237 in human tumor xenografts relative to liver/intestine and serum of the host animals Figure 9 shows the in vitro cellular drug uptake kinetics of CF237 in a human breast tumor cell line and in normal human epithelial and endothelial cells.
The preparation of CF237 is described in commonly owned application PCT/US03/0483, as is the preparation of many other ansamycins, including many geldanamycin derivatives that can be used in connection with various aspects and embodiments of the present invention.
Tumor tissue was a human tumor cell line, MDA435, obtained from the American Type Culture Collection (ATCC), Rockville, MD, IJSA. MDA-MB-435 is a human breast tumor line isolated in 1976 by R. Cailleau, et al. from the pleural effusion of a 31 year old female with metastatic, ductal adenocarcinoma of the breast.
Cailleau R , et al. Long-term human breast carcinoma cell lines of metastatic origin:
preliminary c~aaracterization, In Vitro 14: 911-915, 1978; PubMed: 730202.
Normal human tissues were purchased from Clonetics, the BT474 tumor cells from ATCC.
Briefly, drug was administered in a single dose of 30mg/kg body weight via the intraperitoneal route in a formulation comprising 6 parts PEG400, 1 part ethanol and 3 parts Tween 80 ("PET formulation"). Test animals (3/group) were sacrificed at the indicated times after dosing (as indicated in Figures 7 and 8). Tumors were excised, minced into lmrn3 fragments and frozen at -80°C in cryovials until ready for use, at which time they were thawed and homogenized in acetonitrile, and the solvent then evaporated off under nitrogen. Extractions were then performed on the homogenate using ethyl acetatelwater. Blood samples were taken at the times indicated in Figure 8 by serial bleed from the retro-orbital sinus or the tail vein. Blood was collected into tubes, allowed to clot at room temperature for one hour and serum was collected as the supernatant after centrifugation at 300 X g for 5 minutes. The usual volume of serum available for analysis from the pharmacokinetics studies is 15~.L, although smaller volumes can be used. 485p.L acetonitrile and 15~.L
serum sample (from each time point) are added to a l.SmL siliconized microcentrifuge tube and the mixture vortexed briefly at high speed. The tubes are then centrifuged at 21,OOOxg for 10 minutes, after which the organic layer is transferred to a glass test tube. The tubes containing the organic phase are then placed in a Turbovap set at 40°C for 5-10 min. and the acetonitrile blown off using 25PSI nitrogen.
Once the tubes are totally dry, the sample is reconstituted with 150p.L of Mobile Phase (30%
Mobile Phase B Acetonitrile w! 1%Acetic Acid and 0.5% TEA/70% Mobile Phase A
H20 w/ 1% Acetic Acid and 0.5% TEA for ansamycins , 5% Mobile Phase B
Acetonitrile with 0.05% TFA/95% Mobile Phase B H20 with 0.1% TFA). The tubes ar well mixed and the contents then transferred to HPLC vials or 96-well microplates with a micro-insert. HPLC is then performed on the samples at ~160Bar using an Agilent 1100 series device with a Zorbax 300SB-CI$ column (5uM particle size;
150 x 4.6mm), UV photodiode array detector, and the following phases of solvent (30%
Mobile Phase B Acetanitrile w/ 1 %Acetic Acid and 0.5% TEA/70% Mobile Phase A
H20 w/ 1 % Acetic Acid and 0.5% TEA for ansamycins, 5% Mobile Phase B
Acetoniixile with 0.05% TFA/95% Mobile Phase B H20 with 0.1% TFA). The analysis takes approximately 15-25 minutes per sample, based on method. As controls, spiked serum standards using pooled Balb/C or Nu/Nu mouse serum containing 10, 25, 50, 500 and 5000 ng/mL of the compounds of interest were run for each analytical run per the following table.
Standard ConcentrationMouse Serum1 mg/mL Dilution (n$~~') (~,I,) Standard Scheme (Compound dissolved in Mobile Phase) 5000 497.5 2.5 NA
500 1001tL Mouse Serum +
l O 1tL 5000 ng/mL
Standard 50 200 ~L Mouse Serum +
201tL 500 nglmL
Standard 25 SO ~I Mouse Serum +
SO ltl 50 nglmL Standard 100 pl Mouse Serum 20 ttl 50 ng/mL Standard Resulting data is expressed as ng/ml or nM for serum pharmacokinetics (PK) and as ng drug/g tissue for tumor PK.
Figure 9. 18 x T75 of BT474 (Breast carcinoma) cells were compared to 9 x 5 T75 of RPTEC and HUVEC (normal cells). CF237 was added to flasks of these cells (80-90°!o confluent) at indicated times to a final concentration of luM
in 20m1 volumes. Incubations were at 37°C. Cells were harvested using Sml trypsin/flask at the times indicated in Figure 9 (i.e. 0.5, 2, 4, 8, 16 and 24 hours) neutralized with Sml medium, spun down, resuspended in 1mI PBS buffer, spun down again in an 10 Eppendorf centrifuge for lmin @ 13000 rpm, the supernatant aspirated and the product stored at -20°C for later analysis. Analysis was made by suspending the pellets in 1 mL of lysing buffer on ice for 30 min, after which centrifugation was performed @ 14000 Rl'M for 15 min @ 4°C, and the product suspended in 3 mL of ethylacetate. Extracts were evaporated @ 20 psi f~r 15 min @a 30°C, reconstituted in MPA (25 mM Tris-HCl pH 7.0 40% ACN) and assayed by HPLC as described above. The results are displayed in the following table and in Figure 9:
Time Hour BT 474- RPTEC HUVEC BT BT SD
mean 474-O1 474-02 0.5 8570 203 2603 8838 8302 379.07 2 26500 894 7470 26759 26242 365.37 4 41647 _ 905 9100 42530 40764 1248.61 8 61970 1520 15483 57883 66056 5779.42 16 _1_01_90_21450 16706 77287 126517 34810.46 24 f 97677 1485 11026 94726 100628 4173.41 Example 7: Prophetic Examples of methods fox preparing radionuclide-functionalized or cytotoxin-functionalized geldanamycin derivatives Methods for synthesizing nuclides and intermediates are described in Boehm et al., J. Org. Chem., 1986, 51, 5447-5450; Eng et al., Bull. Chim. Soc.
Belges, 1986, 95, 895-914; Prestwich et al., Tetrahedron 1984, 40, 529-537; Hanson et al., Int. J.
Appli. Radiat. Isot., 1984, 35, 810-812; Corey et al., J. Am. Chem. Soc., 1974, 96, 5581-5583; and Bottaro et al., J. Org. Chern., 1967, 174, 424-427, Synthesis and Applications of Isotopically Labelled Compounds, Volume 7 Ulrich Pleiss (Editor), Rolf Voges (Editor), ISBN: 0-471-49501-8, January 2001; Jalilian et al. J
Pharm Pharmaceut Sci. 2000, 3, 114-124. Two additional citations for preparing radioactive iodine compounds include John et al., An improved synthesis -of [125I]N-(diethylaminoethyl)-4-iodobenzarnide: a potential ligand for imaging malignant melanoma, Nuclear Medicine and Biology (1993), 20(1), 75-9. CODEN: NMBIEO
ISSN:0883-2897. CAN 118:212605 AN 1993:212605 CAPLUS, and Chumpradit, S.; Kung, M. P.; Billings, J.; Mach, R.; Kung, H. F. Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPELT. Journal of Medicinal Chemistry (1993), 36(2), 221-8. CODEN: JMCMAR ISSN:0022-2623. CAN
118:254670 AN 1993:254670 CAPLUS. Based on the foregoing, the following prophetic synthetic schemes and products are hypothesized to be produced and have useful effect according to various aspects and embodiments of the invention.
Scheme I
O OH
I I O H2N ~ I 0 'H I _Na2S204 HO ~2NOC0 I EtOAc HQ OHZ OCO
I
i0 _ i0 i0 _ i0 Bu3Sn ~ I H OH Bu3Sn ~ H ' O
Bu Sn ~ N
3 w I CI O W I O W N I I O
O
---° Y H I A~~ H I
THF, MS 4A H~ ~z OCO I MeON, SiOz HO ~2NOC0_ \ : I
i0 _ i0 i0 _ i0 N
NatzSi, i-izOz O N
H I
CN3COzH,~ HO ~2NOCQ
buffer, 12 h I
i0 ' ,O
Scheme II
H v ~cHz)~ Nhi2 ~cH2)~~N
Bu3Sn~
Bu3Sn' v 'N
H
TNF
- ~ 0 Na~2s~ ~z5~
-----Scheme III
NH ~ZSI
~(CH2)L
125~~
THF
,v Scheme IV
O
Ba(OH)2 THFlH20, 65°C
VIVIC
VIVIe Tf2O ~g(OH)2 (i-Pr NEt CH CI p H
)a ~ a 2 Pd2dba3, CsBr off HzNOCO I
CsF, dioxane Me0 vme _ OMe Scheme V
H ~ H O
HzN~N I I O HN~N O
H I ~~CHa~ I~CHa I I N
ii O H l HO_ ~ZNOCO HO HZNOCO
I NaH, THF
i0 _ i0 r0 _ s0 Scheme VI
N N O ttCHs~ ~~CH3 H O
I I O -----~. /~N~N O
NaH, THF I I
'H I H I
HO ~zNOCO I HO ~~NOCO I
s0 _ i0 i0 _ i0 Scheme VII
H H O
NON (Kl2.2.2JtaF- H H O
I I o ~ NON I I p NaN, THF
o H I H I
HO HZNOCO O
I HO HZNOCO_ I
O ' \ -TosO ~O ~O
yaF i0 ([K/2.2.2J ~ BF - is an aminopolyether potassium complex [Kryotofix 2.2.2] ~
Scheme VIII
H v ,~, taF~
R~sN
Kl2.2.2Jt aF-HO HZNOCO
NaN, TNF
i0 _. i0 /v R = -OTs or CF3S03-Scheme IX
H a HZN~N I I O ~aF~N~
IaF~OTs H
Na OEt, DMF
_ ~ ~O
Scheme X
(CHa)zN a H O CF3SOa -(CHa)aN+
W I N O ~/ I H O
O I I II N O
CHzCIz, CF~S03CH3 O I I
HO H NOCO I ~ p H
HO HZNOCO
,O
i0 - ,O
'BF
H O
I N O
Kryptofixzzz. DMSO, O I I N
SepPak ~ p H
,O
Scheme XI
H v H v I W N I I O I ~ N I I O
(CHa)zN / O H I CFaSOa -(CHa)aN+ i O
HO HzNOCO I CN2CIz, HO H2NOC l0 O _ O CF3S~ O ~
i i s - i0 H v N
I I I O
Krypfofixzza DMSO, ~BF
SepPak O H
HO HzNOCO
,O _ ,O
Scheme XII
CF3SO3 (CH3)3N+
~aF
\ O
O H H O \ I
O N ~ N ~ N Kryptofix222, DMSO O H O H O
O
I H I 1 I I N SepPak ° I I N~N~N I I\ °
OCONH~ OH O H I I \H II H I
I , / HO HpNOCO I I OCONH~ OH HO ~aNOCO
\ I
Ow _ Ow i0 _ i0 _ / \
O~ _ O~ i0 _ i0 Scheme XIII
iCHs)zN
/~N~O H O
O ~ _N J1 CHzCIz, CF3SO3CH3 ---HO HZNOCO I HO OHzNOCO
0 - i0 \ _ ~O
Kryptofixzz2, DMSO, SepPak i' s~
Scheme XIV
~zsl / \
H O
~N O
O
Naizsi yz02 AcOH
> p pN 9 buffer HO H2NOC0 _ I o i Scheme XV
HzN ~ n HzN
O H ~ 2 z a r H
HO H NOCO > OH
z ~ EtOAc HO HzNOCO
i0 _ i0 i0 _ i0 CI C~N CI
H OH CI ~CI
N a ~N o H O
O
CI \ I CI O \ ~ W I N
O
~H I Air ox. O N
HO OHNOCO
TNF, MS 4A z I MeOH, SiOz O H
HO HZNOCO
,O - ,O
i0 - ,Q
Scheme XVI
cl ie0 CIA / H O
I I O THF \ ~ I~ N
N ----~ I I p H I ~'~
HO pHZNOCO I H2N ~ ~ N.~CI O H l HO HzNOCO
,O _ ~p CI
,O _ i Scheme XVII
H a I I O TNF CI~N~N
O H I I I N O
HO HZNOCO I HZN~N-SCI CI O H
HO HZNOCO
CI
3 _ i0 ,O - ,O
* * *
The foregoing examples are not limiting and are merely illustrative of various aspects and embodiments of the present invention. All documents cited are indicative of the levels of skill in the art to which the invention pertains. The reagents used, other than those novel reagents of the invention, are commercially available and/or readily synthesized or acquired by one of ordinary skill in the art without undue effort. The disclosure of each document is incorporated by reference herein to the same extent as if each had been incorporated by reference in its entirety individually, although none of the documents is admitted to be prior art.
One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described illustrate preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Certain modifications and other uses will occur to those skilled in the art, and are encompassed within the spirit of the invention, as defined by the scope of the claims.
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the invention and the following claims.
The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, while the terms "comprising", "consisting essentially of ' and "consisting of," each carries a different meaning as a transition phrase, each such phrase may be used in lieu of the others to demonstrate a different aspect or embodiment of the invention. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described, or portions thereof. It is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modifications and variations of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.
In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group, and exclusions of individual members as appropriate.
Other embodiments are within the following claims.
We claim:
Claims (39)
1. A composition comprising a compound, said compound comprising an HSP90 ligand selected from the group consisting of purines, ansamycins, radicicol, zearalanols, ATP analogs, indoles, chalcones, and benzimidazoles; said HSP90 ligand derivatized with a functional moiety selected from the group consisting of imaging agents, radioactive therapeutic agents, and cytotoxic agents.
2. The composition of claim 1 wherein said ligand is geldanamycin derivatized at one or more of the -8, -11, and -17 positions with said functional moiety.
3. The composition of claim 1 wherein said ligand is geldanamycin derivatized at position -17 with said functional moiety.
4. The composition of any of claims 1-3 wherein said ligand has formula A
wherein X comprises said functional moiety, and wherein positions 4 and 5 are optionally both hydrated (4,5-dihydrogeldanamycin)..
wherein X comprises said functional moiety, and wherein positions 4 and 5 are optionally both hydrated (4,5-dihydrogeldanamycin)..
5. The composition of any one of claims 1-3 wherein said functional moiety comprises a radioisotope.
6. The composition of any one of claims 1-3 wherein said functional moiety comprises a radioisotope selected from the group consisting of Iodine125, Iodine131, 213Bi, Technitium99m, Technitium99, Indium111, Rhenium188, Gallium67, Copper67, Yttrium90, and Astatine211.
7. The composition of claim 5 wherein said radioisotope is selected from the group consisting of 18F, 11C, 13N, 123I, 124h 125I, 131I, and 15O.
8. The composition of claim 1 wherein said compound has a formula selected from among the following group of formulas Radionuclide moieties Radionuclide treatment Radionuclide scanning (Positron Emission Tomography or PET) Common isotopes are: 18F, 11C, 13N, 123I, 124I and 15O
9. The composition of any one of claims 1-3 wherein said functional moiety comprises an imaging agent.
10. The composition of any one of claims 1-5 wherein said functional moiety comprises a radioactive therapeutic agent.
11. The composition of claim 1 wherein said functional moiety is selected from the group consisting of radioisotopes, antibodies, recombinant products, small molecules, antineoplastic agents, nitrogen mustard drugs (mustins), herceptin, taxol, taxanes and taxane derivatives, gleevec, alkylating agents, anti-metabilites;
epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor;
procarbazine;
mitoxantrone; platinum coordination complexes; biological response modifiers/growth inhibitors; hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors, anthracycline drugs, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, tepothilones, discodermolide, pteridine drugs, diynenes, podophyllotoxins, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin, podo-phyllotoxin derivatives, etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel, estramustine, carboplatin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT -11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins, and photoactivatable compounds.
epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor;
procarbazine;
mitoxantrone; platinum coordination complexes; biological response modifiers/growth inhibitors; hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors, anthracycline drugs, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, tepothilones, discodermolide, pteridine drugs, diynenes, podophyllotoxins, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin, podo-phyllotoxin derivatives, etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel, estramustine, carboplatin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT -11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins, and photoactivatable compounds.
12. The composition of claim 1 wherein said compound has a formula selected from the following group of formulas nitrogen mustard or "mustin" moieties
13. The composition of claim 1 wherein said functional moiety is a cytotoxic agent.
14. The composition of claim 13 wherein said compound has a formula selected from the group of formulas of any one of claims 6, 8 or 12.
15. A method of treating or preventing an HSP90-mediated disease, comprising administering to a subject a pharmaceutically effective amount of a composition according to claim 11.
16. A method of treating or preventing an HSP90-mediated disease, comprising administering to a subject a pharmaceutically effective amount of a composition according to claim 8.
17. The method of claim 15 or 16 wherein said disease is a cancer or tumor.
18. The method of claim 17 wherein said cancer or tumor is selected from a melanoma, breast, lung, or prostate cancer or tumor.
19. The method of claim 15 or 16 wherein the cells of said subject express supra-normal levels of Her-2 transcript or protein.
20. The method of claim 15 or 16 wherein cells of said subject express supra-normal levels of HSP90 client proteins.
21. The method of treatment or prevention of claim 15 or 16 wherein said disease is an infection.
22. The method of treatment or prevention of claim 21 wherein said infection is a viral infection.
23. The method of treatment or prevention of claim 15 or 16 wherein said administration is oral or topical.
24. The method of treatment or prevention of claim 15 or 16 wherein said administration is parenteral.
25. The method of treatment or prevention of claim 15 or 16 wherein said administration is in situ.
26. The method of treatment or prevention of claim 15 or 16 wherein said subject is a mammal.
27. The method of claim 15 or 16 wherein said mammal is a human.
28. The method of claim 15 or 16 wherein said treatment is part of a chemotherapy regimen.
29. A method of diagnosing or monitoring the progress or regression of an HSP90-mediated disease, comprising:
administering to the cells of a subject having or suspected of having an HSP90-mediated disease a composition according to any one of claims 1, 5-10, or 12;
and evaluating said cells for the presence of said compound.
administering to the cells of a subject having or suspected of having an HSP90-mediated disease a composition according to any one of claims 1, 5-10, or 12;
and evaluating said cells for the presence of said compound.
30. The method of claim 29 optionally further comprising comparing the amount of compound in said cells with compound in normal cells.
31. The method of claim 29 or 30 wherein said administering is ex vivo.
32. The method of claim 29 or 30 wherein said administering is in vivo.
33. The method of claim 29 or 30 wherein said administering is in situ.
34. The method of claim 32 wherein said administering is selected from the group of administration modes consisting of oral, topical, parenteral, buccal, intravenous, subcutaneous, and intramuscular.
35. The method of any of claims 29-35 wherein said evaluating is performed using positron emission tomography (PET).
36. The method of any of claims 29-35 wherein said cells are tumor or cancer cells.
37. The method of any of claim 29-36 wherein said tumor or cancer cells are selected from the group consisting of melanoma, breast, lung, and prostate.
38. The method of any of claims 29-37 wherein said subject is a mammal.
39. The method of claim 38 wherein said mammal is a human.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USPCT/US02/39993 | 2002-12-12 | ||
PCT/US2002/039993 WO2003050295A2 (en) | 2001-12-12 | 2002-12-12 | Assays and implements for determining and modulating hsp90 binding activity |
PCT/US2003/018776 WO2004054624A1 (en) | 2002-12-12 | 2003-06-12 | Cytotoxins and diagnostic imaging agents comprising hsp90 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2549463A1 true CA2549463A1 (en) | 2004-07-01 |
Family
ID=32592278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002549463A Abandoned CA2549463A1 (en) | 2002-12-12 | 2003-06-12 | Cytotoxins and diagnostic imaging agents comprising hsp90 ligands |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1581261A4 (en) |
AU (1) | AU2003303058A1 (en) |
CA (1) | CA2549463A1 (en) |
WO (1) | WO2004054624A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
CN1759115A (en) | 2002-08-23 | 2006-04-12 | 索隆-基特林癌症研究协会 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7691838B2 (en) | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
US20050020556A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
GB0526615D0 (en) * | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
GB0603880D0 (en) * | 2006-02-27 | 2006-04-05 | Novartis Ag | Organic compounds |
CN100519536C (en) * | 2006-03-21 | 2009-07-29 | 中国医学科学院医药生物技术研究所 | Group of geldanamycin derivative with nucleoside base |
KR20100074177A (en) | 2007-09-10 | 2010-07-01 | 유니버시티 오브 매사추세츠 | Mitochondria-targeted anti-tumour agents |
US20110270151A1 (en) * | 2008-09-08 | 2011-11-03 | The Methodist Hospital Research Institute | Image-guided energy deposition for targeted drug delivery |
US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
WO2015038649A1 (en) | 2013-09-10 | 2015-03-19 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
JP2017505777A (en) | 2014-01-29 | 2017-02-23 | シンタ ファーマスーティカルズ コーポレーション | Targeted therapeutics |
WO2015134464A2 (en) | 2014-03-03 | 2015-09-11 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
EP3131586A4 (en) | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
CN110799194A (en) | 2017-06-20 | 2020-02-14 | 马德里加尔制药公司 | Combination therapy comprising targeted therapeutic agents |
CN111511364A (en) | 2017-06-20 | 2020-08-07 | 马德里加尔制药公司 | Targeted therapeutic agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1098666B1 (en) * | 1998-07-17 | 2013-01-16 | The United States of America, represented by the Secretary, Department of Health and Human Services | Water-soluble drugs and methods for their production |
JP2005510534A (en) * | 2001-11-21 | 2005-04-21 | アクティブバイオティクス インコーポレイティッド | Targeted therapeutics and uses thereof |
-
2003
- 2003-06-12 AU AU2003303058A patent/AU2003303058A1/en not_active Abandoned
- 2003-06-12 CA CA002549463A patent/CA2549463A1/en not_active Abandoned
- 2003-06-12 WO PCT/US2003/018776 patent/WO2004054624A1/en not_active Application Discontinuation
- 2003-06-12 EP EP03741983A patent/EP1581261A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2004054624A1 (en) | 2004-07-01 |
AU2003303058A1 (en) | 2004-07-09 |
EP1581261A1 (en) | 2005-10-05 |
EP1581261A4 (en) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002364566B2 (en) | Assays and implements for determining and modulating HSP90 binding activity | |
CA2549463A1 (en) | Cytotoxins and diagnostic imaging agents comprising hsp90 ligands | |
EP1472230B1 (en) | Ansamycins having improved pharmacological and biological properties | |
US7553979B2 (en) | HSP90-inhibiting zearalanol compounds and methods of producing and using same | |
US8518897B2 (en) | Method of treatment for cancers associated with elevated HER2 levels | |
EP2879675B1 (en) | Compounds and methods for targeting hsp90 | |
CN114315754B (en) | Hydroxamic acid compound and application thereof | |
AU2002310065A1 (en) | Method of treatment for cancers associated with elevated HER 2 levels | |
US20080280878A1 (en) | Methods and Compositions for Treating Chronic Lymphocytic Leukemia | |
You et al. | Design, synthesis and biological evaluation of N-arylsulfonyl carbazoles as novel anticancer agents | |
US20060251574A1 (en) | Cytotoxins and diagnostic imaging agents comprising hsp90 ligands | |
Abdelgawad et al. | Phthalazone tethered 1, 2, 3-triazole conjugates: In silico molecular docking studies, synthesis, in vitro antiproliferative, and kinase inhibitory activities | |
Ghorab et al. | Design, synthesis and molecular modeling study of certain quinazolinone derivatives targeting poly (ADP-ribose) polymerase 1 (PARP-1) enzyme as anti-breast cancer and radio-sensitizers | |
Li et al. | Rational design of phenyl thiophene (pyridine) derivatives that overcome P-glycoprotein mediated MDR in MCF-7/ADR cell | |
Tan et al. | Design, synthesis and biological evaluation of novel dihydroquinolin-4 (1H)-one derivatives as novel tubulin polymerization inhibitors | |
Xing et al. | Discovery of Novel Tetrahydro-β-carboline Containing Aminopeptidase N Inhibitors as Cancer Chemosensitizers | |
Lei et al. | Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments | |
WO2006085330A2 (en) | Use of protein tyrosine kinase inhibitors for the treatment of leiomyomas | |
WO2021207352A1 (en) | Compositions and methods for treatment of anticancer-drug resistant cancers | |
Su et al. | 1, 3, 5-triazines inhibit osteosarcoma and avert lung metastasis in a patient-derived orthotopic xenograft mouse model with favorable pharmacokinetics | |
Jiangzhou et al. | Discovery of proqodine A derivatives with antitumor activity targeting NAD (P) H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase | |
Mohammed et al. | Synthesis and biological evaluation of 4H-benzo [e][1, 3] oxazin-4-ones analogues of TGX-221 as inhibitors of PI3Kβ | |
WO2009067697A1 (en) | Therapeutic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |